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Abstract 
 
Effect of the Ketogenic Diet on Seizures in the Methionine Sulfoximine Model of Mesial 
Temporal Lobe Epilepsy 
Clayton Haldeman  
2013 
About two-thirds of patients with one of the most common forms of epilepsy – mesial 
temporal lobe epilepsy (MTLE) – cannot control their seizures with current antiepileptic 
drugs.  More efficacious therapies for this disorder are therefore needed.  A low 
carbohydrate, high fat – i.e. ketogenic – diet (KD) is a highly effective treatment for 
many types of epilepsies; however, whether the diet is effective in reducing seizures in 
MTLE is relatively unexplored.  As a first step towards understanding the role of the KD 
in MTLE, we investigated whether the diet reduces the frequency and severity of seizures 
in a novel rat model of this disorder.  
Thirty-eight male Sprague Dawley rats were implanted with an osmotic pump injecting 
the glutamine synthetase inhibitor methionine sulfoximine (MSO) into the polymorphic 
layer of the right hippocampus. Beginning immediately after surgery, the rats were 
continuously monitored with intracranial EEG and simultaneous video recordings. One 
week post-surgery, rats were assigned to either a KD with 20% caloric restriction or a 
standard chow (SC) fed ad libitum and further monitored for another two to four weeks. 
EEG analysis was correlated with video recordings to determine the frequency and 
severity of seizures according to a modified Racine scale.   
There was no significant difference in the weekly frequency of seizures in rats treated 
with the KD versus SC.  Neither was there any difference in the severity of seizures 
between rats treated with the KD and rats fed SC.  These data should be interpreted with 
caution because animal models of MTLE may respond differently to the KD than humans 
with the disorder.  Also, a lack of significant difference does not rule out the presence of 
a real, but small difference that cannot be detected due to the statistical power of the 
present study.  Nevertheless, the data suggest that the KD may not be an effective 
treatment for MTLE. 
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Chapter 1: Introduction 
There are approximately 1.6 million people in the United States suffering from epilepsy1. 
While most patients with epilepsy maintain good control over their disease, temporal lobe 
epilepsy (TLE) is often drug resistant with upwards of 40% of patients continuing to have 
seizures despite treatment with appropriate anti-epileptic drugs (AEDs)2,3. Uncontrolled 
seizures greatly impact patient’s quality of life with significant psychological, 
economical, and social impact4. Furthermore, in animal studies, recurrent seizures have 
been shown to lead to cell loss and synaptic reorganization, causing permanent brain 
injury5. Thus, there is a need for greater understanding of the pathophysiology of TLE 
and a necessity to develop more efficacious therapies for this disease.  
One possible therapy for combating medically intractable seizures, which has regained 
popularity recently, is the ketogenic diet (KD). The KD was originally developed in the 
1920s, when relatively few antiepileptic medications were available, to imitate the 
metabolic effects of starvation after observations that fasting decreased seizure 
frequency6. The KD is a high-fat, low carbohydrate diet that improves the brain energy 
stores in patients with epilepsy7, reduces the frequency of spontaneous recurrent seizures 
in many types of this disease, particularly pediatric epilepsies8, and protects against 
neuronal loss in animal models of TLE9. Though a number of different mechanisms of 
action of seizure reduction have been proposed for the diet, there is no consensus 
currently which hypothesis is correct. Moreover, whether the KD is an effective and 
sustainable long-term treatment for patients with MTLE has not been fully established.  
The goal of this thesis is to investigate whether the KD reduces the frequency and 
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severity of seizures in an animal model of MTLE.  Such information would address the 
lack of knowledge on the diet’s efficacy in MTLE, and could potentially provide us with 
an animal model for studies on the mechanisms of the KD in this disorder.    
1.1 Epilepsy Review 
Epilepsy is a chronic neurologic condition affecting nearly 50 million people 
worldwide10. Epilepsy is not a single disease but a variety of disorders reflecting 
underlying brain dysfunction characterized by recurrent seizures. Seizures are defined by 
The International League Against Epilepsy (ILAE) as “a transient occurrence of signs 
and/or symptoms due to abnormal excessive or synchronous neural activity in the 
brain.”11 Most seizures can be broadly classified into one of two types: partial 
(localization-related) or generalized12.  
Generalized seizures are abnormal synchronous electrical activity that involves 
both hemispheres at onset and consciousness is lost from the start. Just as with partial 
seizures, generalized seizures are classified primarily based on clinical findings13. For 
example, during absence seizures the patient abruptly loses consciousness and may 
appear to stare blankly for a short period of time, then suddenly regain consciousness 
with no residual deficits. Generalized tonic-clonic seizures are characterized by 
prolonged contraction of skeletal muscle during the tonic phase, followed by rapid 
alternation of muscle relaxation and contraction during the clonic phase. 
Partial seizures, also known as localization-related or focal seizures, are abnormal 
bursting electrical activity that occurs in a localized region of the brain. Partial seizures 
can be further broken down into simple partial and complex partial seizures. Simple 
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partial seizures spare consciousness, while complex partial seizures result in loss of 
consciousness. Partial seizures may begin with localized motor, sensory, autonomic or 
psychic symptoms. Partial seizures can often times be preceded by an aura, or 
premonition, that patients can recognize as a forewarning to an impending seizure. When 
simple or complex partial seizures spread to involve the entire brain, they are termed 
secondarily generalized seizures. Secondarily generalized seizures are often tonic-clonic 
seizures that begin with posturing or head and eye deviation. 
TLE is a particularly devastating type of focal epilepsy characterized by 
spontaneous, progressive partial seizures originating in the temporal lobe.  The seizures 
may or may not secondarily generalize.  The estimates of the prevalence of TLE vary14. 
In an epidemiological study in Rochester, MN, the incidence rate of TLE was 10.4 per 
100,000 between 1945 and 1964, and 6.5 between 1935 and 194415. While many of these 
patients maintain good control of their seizures with medication, up to 40% of patients 
with TLE are resistant to anti-epileptic medications3.  
Several schemes have been proposed for further classification of TLE.  One of 
these schemes divides the disorder into two types based on the anatomic origin of the 
seizure focus: Seizures that originate in the medio-basal (limbic) temporal structures, 
mesial temporal lobe epilepsy (MTLE), and seizures that originate in other (usually 
lateral) parts of the temporal lobe. The hippocampus is located in the medial temporal 
lobe, and it is commonly regarded as the site of origin for MTLE, and surgical removal of 
the hippocampus often results in good control of seizures in these patients16. Pathological 
examination of the resected hippocampus in many of these patients exhibit a 
characteristic pattern of pathological changes, notably atrophy, induration, glial 
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proliferation, and preferential loss of neurons in CA1, CA3, and the dentate hilus.17 
Mossy fiber sprouting and selective loss of somatostatin and neuropeptide Y-containing 
hilar neurons can also be seen18,19. All these changes are collectively known as 
hippocampal sclerosis (HS). 
For patients with MTLE, the first episode of seizures typically begins during the 
first 15 years of life. Some patients initially respond well to AEDs, and their seizures can 
be controlled with medications for a time. Typically, however, seizures return around 
adolescence or early adulthood. Auras are frequent, with visceral auras being the most 
common type. Complex partial seizures are the most frequent type of seizures in these 
patients, with generalized tonic-clonic seizures occurring occasionally20. 
What causes MTLE to develop is currently unknown.  However, there is an 
association between the development of MTLE and the presence of early risk factors 
such as prolonged childhood febrile seizures, trauma, or intracranial infection21,22. There 
appears to be a progressive aspect to MTLE as well, that once set in motion, the disorder 
continues to evolve over time20. Despite the fact that multiple new AEDs have come on 
the market in recent years, many patients remain refractory to medications. There is a 
need for more effective therapies with fewer side effects. It is important to understand the 
underlying mechanism of MTLE in order to develop improved therapies. 
1.2 Possible Mechanisms of MTLE 
Despite the fact that focal seizures are the most common type of seizures, the 
underlying mechanism of seizure generation remains poorly understood. Much of our 
current knowledge on MTLE comes from human studies using scalp and intracranial 
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EEG recordings, brain microdialysis, neuroimaging, and pathological investigations of 
surgically resected brain tissue.  Many investigations also involve various animal models 
of MTLE.    
1.2a Glutamate Hypothesis 
 Glutamate is the most abundant excitatory neurotransmitter in the brain. 
Glutamate concentrations in plasma are 50-100 micromol/L but only 0.5-2 micromol/L in 
the brain extracellular fluid (ECF)23. The low ECF concentrations, which are essential for 
optimal brain function, are maintained by neurons, astrocytes, and the blood-brain barrier 
(BBB). Glutamate does not readily cross the BBB and therefore the majority of glutamate 
is synthesized from blood-derived glucose and transamination of alpha-ketoglutarate24. 
An excess of extracellular glutamate in the hippocampus may be one of the key 
molecular causes of seizures and brain damage in MTLE. In in vivo microdialysis studies 
have demonstrated that interictal extracellular glutamate is elevated five-fold more in the 
epileptogenic vs. the nonepileptogenic human hippocampus25. Unexpectedly, in those 
patients with hippocampal sclerosis, interictal extracellular glutamate concentrations are 
considerably higher than in patients without this pathology, even though patients with 
sclerosis have lost up to 80% of neuronal density26-28. Extracellular hippocampal 
glutamate has also been shown to increase six-fold above the interictal level during a 
seizure and remain elevated for at least 20 minutes after cessation of seizure activity, 
suggesting a role for glutamate in triggering seizures29. Intraoperative isotopic tracer 
(13C) studies suggest that the accumulation and impaired clearance of glutamate in 
MTLE is due to slowing of the glutamate–glutamine cycle metabolism in the sclerotic 
and epileptogenic hippocampus compared with the nonsclerotic and nonepileptogenic 
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hippocampus or the normal occipital neocortex30. Finally, oral and subcutaneous 
administration of glutamate and its analogues has been shown to causes seizures in rhesus 
monkeys, cats, and mice.31 All these finding taken together suggest that glutamate is a 
crucial element in the pathophysiology of this disease. 
 Dysfunction of glutamine synthetase (GS) in astrocytes has also been 
hypothesized to cause  an excess of extracellular brain glutamate. GS is necessary for the 
metabolism of glutamate to glutamine, and the enzyme is deficient in discrete areas of 
surgically resected, epileptogenic hippocampal formations from patients with MTLE. Eid 
et al demonstrated a 35-40% loss of GS protein and activity in astrocytes in the sclerotic 
hippocampus when compared to cadaver hippocampi or patients with   MTLE and no 
HS32. It was postulated that the  deficiency in GS could slow the conversion of glutamate 
to glutamine and lead to a buildup of astrocytic and extracellular glutamate.  However, 
the lack of GS in patients with MTLE does not necessarily mean that a deficiency in GS 
causes seizures, and animal studies are required to address this issue. Notably, infusion of 
the GS inhibitor, methionine sulfoximine  (MSO) into the hippocampus in rats, results in   
recurrent seizures  33. Moreover, MSO-treated rats sometimes exhibit neuropathological 
changes similar to HS, such as unilateral atrophy of the hippocampus with loss of 
neurons in the CA134.  Taken together, these findings implicate a loss of GS in the 
causation of MTLE. 
1.2b Role of Astrocytes 
 Astrocytes play a key role in the regulation of the amount of glutamate in the 
extracellular environment. Perivascular end-feet, which are astrocytic processes 
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surrounding microvessels, are believed to take up blood glucose before it reaches the 
neuron and ultimately convert it into glutamate via one of several enzymes such as 
glutamate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, or 
branched-chain aminotransferases35. Astrocytes also seem to be the only cell in the brain 
with the ability to replenish TCA cycle intermediates that are used up in the synthesis of 
glutamate from alpha-ketoglutarate, a process known as anaplerosis. This process is due 
to the exclusive presence of pyruvate carboxylase in astrocytes36. Astrocytes also 
significantly influence glutamate catabolism by using the enzyme GS, which is 
preferentially localized to these cells37. While several neuronal vesicular glutamate 
transporters (VGLUT-1, 2) and excitatory amino acid transporters exist, the majority of 
synaptic glutamate is taken up by astrocytes and the aminoacid is converted to glutamine 
by GS, then shuttled to neurons, where, once inside, glutamine is converted back to 
glutamate via phosphate activated glutaminase38,39. 
1.2c GABA 
Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in 
the brain, and has been implicated in seizure origin and spread40. GABA is formed within 
GABAergic axon terminals by decarboxylation of glutamate. After being released into 
the synapse GABA can act on one of two types of GABA receptors: GABA-A receptors 
or GABA-B receptors. GABA-A receptors are ligand-gated ion channels that 
hyperpolarize neurons by increasing chloride entry into the cell. GABA-A facilitates the 
early portion of GABA mediated inhibitory post-synaptic potential. GABA-B works by 
increasing potassium conductance, decreasing calcium entry, and inhibiting the 
presynaptic release of other transmitters. It is responsible for the late portion of GABA 
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mediated inhibitory postsynaptic potential. In the Spencer and During microdialysis study 
cited above, GABA was found to increase during seizures, however, this increase was   
greater in the non-epileptogenic vs. the epileptogenic hippocampus29.  They demonstrated 
the number of GABA transporters is reduced in the epileptogenic hippocampus, and 
suggested that this reduction impairs non-vesicular GABA release secondary to cell 
membrane depolarization, resulting in insufficient GABA release to suppress seizure 
activity41. GABA synthesis is impaired in human pyridoxine (vitamin B6) deficiency, a 
disorder characterized by severe refractory neonatal/infantile seizures42. Several animal 
models have shown the importance of GABA’s role in epilepsy as well. For instance, 
DBA/2 mice, which are particularly susceptible to audiogenic seizures, have reduced 
numbers of   high-affinity GABA receptors, and reduced benzodiazepine binding in 
multiple brain areas43,44. Finally, drugs that enhance GABA concentration in the synapse 
are often effective ant-epileptic drugs. Vigabatrin, which is an irreversible suicide 
inhibitor of GABA transaminase, and Tiagabine, which blocks GABA reuptake into 
neurons and glia, are two such examples.  
1.2d Inflammation 
 Inflammatory processes have also been implicated in epilepsy. Early clinical 
evidence for inflammation in seizures came from several sources. Febrile seizures, which 
involve the acute release of cytokines and other inflammatory mediators in the brain, 
were one early clue45. Chronic brain inflammation, such as in Rasmussen’s encephalitis, 
a devastating childhood auto-immune disease, is characterized by severe progressive 
seizures as well46. There is clinical evidence that steroids or other anti-inflammatory 
treatments can be effective anticonvulsants in some childhood epilepsies that are resistant 
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to traditional AEDs 47,48. Finally, several inflammatory mediators are altered in surgically 
resected hippocampi in patients with TLE49.  
A question that arises is whether inflammation is a cause or a consequence of 
epilepsy, and several experimental models have tried to address this. In rats, induction of 
limbic status epilepticus or recurrent spontaneous seizures results in activation of 
inflammatory cytokines (IL-1, IL-6, TNF) in the hippocampus, supporting the idea that 
inflammation might be an intrinsic part of the epileptogenic process50. However, it has 
also been shown that brain inflammation can increase neuronal excitability and 
predisposition to seizures. There is strong evidence that IL-1β, TNF, IL-6, prostaglandin 
E2 all play an active role in seizure generation51. The complement cascade, leading to 
formation of the membrane attack complex (MAC), has also been shown to generate 
seizures when injected sequentially into the hippocampus of rats52. These results taken 
together suggest a cyclical process in which both seizures and inflammation seem to 
reinforce one another. 
1.3 Ketogenic Diet 
 The ketogenic diet (KD) was originally developed in the 1920s, when relatively 
few antiepileptic medications were available, to imitate the metabolic effects of starvation 
after observations that fasting decreased seizure frequency6. It had a brief surge in 
popularity, then was quickly eschewed once the first truly effective AED, phenytoin, was 
developed in the late 1930s. . With nearly 1/3 of epilepsy patients not adequately 
controlled on current AEDs, the KD has regained popularity recently as an alternative 
way to combat medically intractable seizures53.  
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1.3a Efficacy of the KD 
 The initial efficacy studies of the KD were done at Johns Hopkins Hospital in 150 
children54.  Before the study, all children combined had an average number of 410 
seizures per month. They had failed to have their seizures controlled despite being 
previously tried on a mean of 6.2 medications and were on an average of 1.97 
medications at the time of diet initiation. After 3 months of treatment with a KD, 34% of 
the children had >90% decrease in seizures and at 6 months, 32% had a >90% decrease in 
seizures. One year after beginning the treatment with the KD, 55% of children remained 
on the diet; 7% were seizure free, and 20% had a 90% decrease in seizures.  A 
randomized control trial of 103 patients was published recently that was similarly 
efficacious55. 
The KD has been shown to be effective in a variety of types of epilepsy 
syndromes and seizure types. The largest clinical trial to date showed no statistically 
significant difference in efficacy by seizure type54.  It has been shown to be quite 
effective, even within the first 48 hours of its application, in decreasing the incidence of 
atonic or myoclonic seizures in children with Lennox-Gastuat syndrome (LGS)56. In a 
trial of seven girls with Rett syndrome, the KD improved seizure control in 5 of them and 
also improved social interaction, and reduced stereotypical behaviors57. It is felt to be the 
therapy of choice for Glut-1 deficiency and very effective in Dravet Syndrome and 
Myoclonic Astatic Epilepsy.58 A study comparing efficacy of the KD in treating 
generalized seizures vs. focal seizures showed a tendency towards improved outcome in 
those with generalized seizures compared to those with focal seizures, but the diet was 
effective in both types, and no statistical differences were found59. Than et al. also 
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showed that an early, dramatic response to the KD (defined as those patients becoming 
seizure free after two weeks on the KD) was most often observed in generalized seizures, 
rather partial seizures in children.60 
Though traditionally thought of as a treatment for pediatric epilepsies, there is 
evidence that the KD works in adults as well. Kossoff et al tried a group of 30 adults who 
had at least weekly seizures and had failed at least 2 AEDs on a modified Atkins diet (a 
less restrictive KD) and obtained encouraging results61. At 1 and 3 months, 47% of 
patients had a >50% seizure reduction, and after 6 months on the diet, 33% had a >50% 
seizure reduction. Previously, it was believed that the KD is more effective in children 
due to an enhanced ability to extract ketones form the blood or due to their metabolic 
capacity but may be due to poor tolerance of the diet in adults. 
Importantly, the diet has also been shown to have antiepileptic effects (i.e. 
interfering with the process of developing recurrent unprovoked seizures) in addition to 
the previously discussed anticonvulsive effects. In a 3 to 6 year follow up of children who 
had been on the KD, Marsh et al. showed that children who discontinued the diet, some 
after only a few months, had long-term reductions in seizure even after the diet was 
stopped.62 
1.3b Practical Issues and Adverse Effects of the KD 
One obstacle in the use of the KD in adults is compliance with the strict dietary 
guidelines. In a small study in which the full KD was tried on adults, 4 of the 11 had 
discontinued the diet by 8 months follow-up63.  The most challenging aspect of the KD 
for most people is abstaining from carbohydrates. The traditional KD is a 4g fat/1g 
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combined protein and carbohydrate64.  Most centers, when initiating the diet, hospitalize 
patients while they undergo an initial phase of fasting to achieve ketosis65. Once robust 
ketosis is confirmed, patients begin the KD and are supplemented with a fat-soluble 
vitamin supplement and additional calcium. Table 1 shows a sample KD for 1 day. 
Table 1. Sample ketogenic diet for 1 day (from Sirven et. al) 
Breakfast Lunch Dinner 
2 medium eggs  
1 sausage patty  
11 tsp butter  
3 tbs heavy whipping cream 
2 hot dogs 
2 lettuce leaves, 1 thin slice 
tomato  
3.5 tbs mayonnaise 
Chicken 1.5 ounces  
½ cup green beans, 2 tsp 
butter  
4 tbl vegetable oil 
 
Side effects of the KD are rarely so severe that the diet must be discontinued.66 
Acidosis, hypoglycemia, gastrointestinal distress, dehydration, and lethargy can occur 
early after treatment with the KD is begun. These effects are typically short lived when 
they do occur and can be relatively easily managed.  
Longer-term adverse effects include increases in blood lipid levels and 
cholesterol. After 6 months on the diet LDL levels increased an average of 50 mg/dL, or 
2 standard deviations in a group of 141 children67. Triglycerides and atherogenic apo-B 
containing lipoproteins increased and HDL levels decreased in this same group. However 
Kossoff has shown that lipid levels normalize with time and there appears to be no 
evidence of increased cardiovascular or hepatic disease.68 
Kidney stones are another longer-term complication of the KD. They occur in 
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about 6% of patients and present, on average, after about 7 months on the KD.69  
Children on the KD are at increased risk for kidney stones for a number of reasons. The 
diet creates an acidosis which promotes hypercalciuria, secondary to increased bone 
demineralization, hypocitrauria, and low urine pH.70 In addition, many patients on the 
diet are fluid restricted, which can lead to supersaturation of urine with calcium or uric 
acid, creating a nidus for stone formation. The risk of kidney stones can be decreased 
with supplementation with potassium citrate 
Children on the diet gain minimal weight and height within the normative values 
for their age71. However, the growth of young children (<1 year) seems to be slowed 
more than that of older children, and they should be monitored carefully. Most children 
on the KD for more than 6 years were in the bottom 10% for height and weight.72 Though 
there is some data to suggest that children grow rapidly once the diet is discontinued.73  
1.3c Possible Mechanism of Action of the KD 
As mentioned above, the classic ketogenic diet consists of a 4:1 ratio of fats to 
protein and carbohydrates. Severely restricting carbohydrates from the diet leads to 
glycogen depletion in the liver and decreased glucose utilization by the body. In lieu of 
glucose, fatty acids are metabolized for energy. Beta-oxidation of fatty acids takes place 
in mitochondria in the liver, the end product of which is acetyl-CoA. When TCA cycle 
intermediates are depleted, as they are in long-term carbohydrate restriction, acetyl-CoA 
accumulates and is shuttled down the ketogenesis pathway, producing the ketone bodies: 
acetoacetate, acetone, and β-hydroxybutyrate. These ketone bodies become the major fuel 
source for the brain while on the KD. 
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Though a number of different mechanisms of action of seizure reduction have 
been proposed for the diet, there is no consensus currently which hypothesis is correct.74  
The ketone bodies themselves have been a major area of investigation. Peterman, in his 
preliminary report of KD, postulated that the acetoacetate acid acts as an anesthetic agent 
that penetrates the CNS to suppress seizures.64. More modern experience with the diet has 
shown that the anticonvulsant effect rises slowly, as blood levels of ketones rise, and then 
fall off abruptly if ketosis is eliminated by ingesting carbohydrates.75  Additionally, β-
hydroxybutyrate blood levels appears to correlate with seizure control in some 
individuals.76 And in animal models, direct injection of ketone bodies have been shown 
to be anticonvulsant in mice with audiogenic seizures.77 These findings, together, seem to 
hint at a direct role for ketone bodies in seizure reduction. 
Inhibition of vesicular glutamate loading 
If ketone bodies are directly limiting seizure activity, what are they targeting? 
Recently research has shown that ketone bodies are physiological modulators of VGLUT, 
which transports glutamate into synaptic vesicles. When cultured neurons were perfused 
with acetoacetate at a concentration of 1 mM (a concentration expected in humans during 
the KD) VGLUT2 was inhibited.78 Acetoacetate competes for the Cl- binding site on 
VGLUT, turns the transporter off upon binding, leading to decreased glutamate storage in 
vesicles, and therefore less glutamate release by neurons. In hippocampal slices, 
acetoacetate was shown to reduce excitatory glutamatergic synapse transmission in CA1 
neurons. Additionally, when the proconvulsant K+ channel blocker 4-aminopyridine was 
infused in rats, neuronal hyperexcitability was reversed by direct infusion of 
acetoacetate.78  
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Reducing neural excitability via KATP channels 
 One consequence of ketone body metabolism in neurons is increased ATP 
production by mitochondria and a decrease in glycolytic ATP production.79 Earlier work 
has shown that glycolytic ATP is synthesized by membrane bound enzymes and 
deposited in membrane-associated compartments, where it can be used by Na+/K+ 
pump.80 When ketone body metabolism shifts the bulk of ATP production to the 
mitochondria, ATP reserves in membrane-associated compartments are depleted. This 
decrease in membrane associated ATP leads to opening of the membrane bound KATP, 
which in turn leads to hyperpolarization and decreased excitability.81 Yellen et al have 
shown that when acetoacetate or β-hydroxybutyrate are applied to brain slices in a 
constant level of glucose, spontaneous firing is decreased by approximately 15%.82 
Spontaneous firing was decreased further on cells that fired faster, known as “use 
dependence”. They also demonstrated that the decreased excitability effect is eliminated 
in KATP blocking drugs are used or when the Kir6.2 subunit is knocked out genetically.  
The role of KATP channels in the seizure suppressing effects of the KD have been 
further explored using BAD knock out mice.83  BCL-2- associated Agonist of Cell Death 
(BAD) is a pro-apoptotic member of the BCL-2 family that regulates the release of 
apoptogenic factors from mitochondria. In addition to its role in apoptosis, it has recently 
been shown that BAD modulates glucose metabolism via phosphorylation of the serine 
155 residue on glucokinase in multiple types of cells.84 When BAD is knocked out in 
mice, glucose metabolism is reduced and cells undergo changes in metabolism similar to 
that seen during ketone body metabolism.83 Furthermore, mice with BAD knocked out 
have been shown to be resistant to seizures caused by kainic acid and by 
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pentylenetetrazole (PTZ), a GABAergic antagonist. The open probability for KATP 
channels was significantly increased in these mice. Additionally, when KATP channel was 
made dysfunctional by deletion of the Kir6.2 subunit, the BAD knockout mice reverted 
back to wild type seizure sensitivity, offering compelling evidence for KATP meditating 
BAD’s effect on neuronal excitability.83 
 
MCT1 
Upregulation of the monocarboxylate transporter 1 (MCT1) is another possible 
mechanism of action of the KD. MCT1 is found throughout the brain and is a key 
transporter of blood derived monocarboxylates such as pyruvate, lactate and the ketone 
bodies acetoacetate and beta-hydroxybutyrate.85 MCT1 is also a transporter of acidic 
drugs, such as the antiseizure medication valproic acid, across the blood brain barrier.86 
Eid and colleagues recently showed that patients with TLE were severely deficient in 
MCT1 on the endothelial cell membrane of microvessels in the epileptogenic 
hippocampal formation.87 This finding suggests that the uptake of blood-derived 
monocarboxylate fuels and possibly also antiepileptic drugs are impaired in the seizure 
focus of the brain. The loss of MCT1 on microvessels has been reproduced in three novel 
rat models of TLE, indicating that MCT1 is of key importance in the pathophysiology of 
the disease.88 
Interestingly, Leino in 2001 showed that adult, non-epileptic rats, when fed a KD, 
upregulate brain MCT1 by 8 fold.85 A key question therefore is whether the therapeutic 
action of the KD in epilepsy can be explained by an upregulation of MCT1 in 
epileptogenic areas of the brain. It is yet to be shown, however, that MCT1 levels are 
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increased in response to a KD in epilepsy. 
1.4 MSO Model of TLE 
 Over the years there have been many methods of provoking seizures in animals. 
However, it is critical that disease oriented translational science experiments reflect the 
underlying human pathology as closely as possible, and as consistently as possible. 
Systemic administration of kainic acid or injection of pilocarpine results in severe status 
epilepticus, however the seizures can be lethal and widespread brain damage, which is 
not a feature of TLE, is often seen as well. 89,90 Models such as amygdala kindling and 
prolonged hyperthermia produce seizures, but often do not result in spontaneous, 
recurrent seizures.91,92 However, the MSO model, in which MSO is continuously infused 
unilaterally into the hippocampus, replicates many of the key features of TLE. Episodes 
of spontaneous, recurrent seizures – many of these are partial – with a low mortality rate 
are consistently seen in this model. Pathological examination has shown a range of 
histologies, from little to no neuronal loss in the hippocampus to hippocampal sclerosis-
like pathology, to extensive neural degeneration and gliosis. MSO acts by inhibiting 
glutamine synthetase, which has been shown to be deficient in resected hippocampi of 
humans with TLE, so its mechanism of action may be relevant to one possible etiology of 
TLE as well. 
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Chapter 2: Hypothesis 
We hypothesize that the ketogenic diet combined with 20% caloric restriction will reduce 
seizure burden in the rat MSO model of TLE.  
 
Specific Aims: 
1.) To asses the effect of the KD and caloric restriction on the total number of 
seizures in the rat MSO model of TLE 
2.) To asses the effect of the KD and caloric restriction on the severity of seizures in 
the rat MSO model of TLE 
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Chapter 3: Methods 
3.1 Chemicals and Animals 
All chemicals were obtained from Sigma Chemical Co. (St. Louis, Mo.) unless 
otherwise noted. Adult, male Sprague Dawley rats were used in this study (200 to 250 g; 
Charles River Laboratories, Wilmington, Mass.). The rats had free access to water and 
were housed on a 12-h light/dark cycle, with lights on from 7 a.m. to 7 p.m. The animal 
care and use procedures were approved by the Institutional Animal Care and Use 
Committee of Yale University. All experiments were performed in accordance with 
current guidelines. 
 
3.2 Diet 
After implantation of the MSO cannula, rats were divided into two groups: an 
experimental group fed a ketogenic diet with 20% caloric restriction (Ketovolve, Solace 
Nutrition, CT, n=12), and a control group fed standard rodent chow (SC) (Teklad Rodent 
Diet, Harlan, n=26) ad libitum. The experimental group was given a ketogenic diet 
consisting of 89% fat and 9% protein (based on caloric content) and 20% caloric 
restriction for 3 weeks in one set of animals, and 4 weeks in another. The diet was started 
one week after cannula implantation and MSO infusion and continued until the rats were 
euthanized. This diet has been shown to produce significant ketosis in previous 
studies.85,93  
Normal caloric intake was determined by monitoring the rats’ caloric intake for 1 
week prior to surgery. At the end of 1 week the average daily caloric intake was 
calculated, then reduced by 20%. For example, 300g of standard chow was placed in the 
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rat’s feeder. Seven days later the food was removed and 121g remained. The rat ate 178g, 
which averages to 25.5g/day or 84kcal/day. Reducing the calories by 20%, this rat would 
be fed 67kcal/day, or 9.5g/day of Ketovolve powder. After an initial fasting period of 24 
hours, the rats on the KD were fed once per day. See table 2 for comparison of the caloric 
contents of the diets. 
 
Table 2. Comparison of macronutrients of standard chow vs. KD 
Diet kcal/g % Protein % Fat % Carbs 
Standard Chow 3.3 20 13 67 
Ketogenic Diet 7.1 8.7 89.2 2.1 
 
3.3 Surgery 
The rats were anesthetized with 1% to 2% Isoflurane (Baxter, Deerfield, Ill.) in O2 
and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, Calif.). A 30-gauge 
stainless steel cannula attached to a plastic pedestal (Plastics One, Roanoke, Va.) was 
introduced through a burr hole in the skull and into the right hippocampus, using the 
following coordinates with bregma as the reference: AP=−5.6 mm, ML=5.3 mm, 
DV=−6.5 mm. The cannula was cemented to the skull using cyanoacrylate and connected 
via plastic tubing to a subcutaneously implanted Alzet osmotic pump (Model 2004, 
Durect Corp., Cupertino, Calif.). This pump holds a total volume of 200 µL and delivers 
a continuous flow of 0.25 µL/h for ∼28 days (as per manufacturer's specifications). The 
pumps were filled with MSO (2.5 mg/mL; dissolved in 0.9% NaCl) to achieve a delivery 
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of 0.625 µg of MSO per hour. MSO delivery was started as soon as surgery was 
completed. 
Two unipolar electrodes (E363/2/SPC stainless steel electrode, Plastics One) with 
bare diameter of 0.200 mm and insulated diameter of 0.230 mm, were introduced into the 
dorsal hippocampus to record continuous bilateral intrahippocampal EEG activity in 
freely moving, awake animals. Approximately 1 mm of insulation was stripped from the 
tip of each electrode. The coordinates used were as follows: AP= − 3.3 mm, ML = 2.5 
mm, DV = − 3.9 mm. One electrode was inserted into each hippocampus. A third depth 
electrode was positioned in the epidural space near lambda to serve as the reference. A 
screw electrode was positioned in the occipital bone to serve as the ground. 
The female socket contacts on the end of each electrode were inserted into a 
plastic pedestal (Plastics One), and the entire implantation was secured by UV light cured 
acrylated urethane adhesive (Loctite 3106 Light Cure Adhesive, Henkel Corp., Rocky 
Hill, Conn.). 
 
Image 1. Rat in stereotactic frame undergoing surgery. 
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3.4 Different length of recording times 
We initially recorded all of the animals for 3 weeks post surgery, i.e. 1 week on standard 
chow and 2 weeks on the KD. After analyzing the data, we saw no significant difference 
in the number or severity of seizures between the groups.  However, there was a trend 
towards decreased severity of seizures during the 3rd week. We decided extended the 
study to 5 weeks (i.e. 1 week on standard chow, 4 weeks on the KD) in subsequent 
animals, in order to investigate the trend over a longer time period. As a result, there are 
fewer animals in the study during the 4th and 5th week. 
 
3.5 Video-intracranial EEG monitoring 
The experimental setup for recording video-EEG was adapted from Bertram et 
al.94 The rats were placed individually in custom-made Plexiglas cages. A spring-
covered, 6-channel cable was connected to the electrode pedestal on one end and to a 
commutator (Plastics One) on the other. A second cable connected the commutator to the 
digital EEG recording unit (Ceegraph Vision LTM, Natus Bio-logic Systems Corp., 
Mundelein, Ill.). Digital cameras with infrared light detection capacity were used to 
record animal behavior (two cages per camera). The digital video signal was encoded and 
synchronized to the digital EEG signals. Seizures were identified by visual inspection of 
the EEG record. Seizures were defined by EEG characteristics and not by the duration of 
the discharge. Specifically, seizures displayed distinct signal changes from background 
(interictal) activity. Such signal changes included sustained rhythmic or spiking EEG 
patters and a clear evolution of signal characteristics from onset to termination. 
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Subclinical seizures were distinguished from clinical seizures by examination of the 
video record. The start and stop points of seizures were identified by the following 
commonly used method. By visual inspection of the EEG, we determined a point that was 
unequivocally within the seizure. Next we moved backward in time to determine the 
seizure start time as the first point where the EEG was different from background activity 
and forward in time to establish the seizure end time. The video record was examined to 
stage the seizures, using a modification of Racine's criteria, as follows: Subclinical, no 
remarkable behavior; stage I, immobilization, eye blinking, twitching of vibrissae and 
mouth movements; stage II, head nodding, often accompanied by facial clonus; stage III, 
forelimb clonus; stage IV, rearing; stage V, rearing, falling and generalized 
convulsions.95 
 
Image 2. Post-surgery rat in Plexiglas cage undergoing continuous video and intracranial 
EEG monitoring. The rat is exhibiting a stage IV seizure with rearing. 
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3.6 Blood glucose and ketone monitoring 
Ketone and glucose levels were taken from rats in the afternoon prior to being fed on a 
weekly basis starting the day of surgery (day 0) and continued until perfusion date. Rats 
were anesthetized using 1-2% isoflurane prior to being pricked by an 18g needle at the 
end of its tail to draw blood.  Between rats, the needle was cleaned with alcohol. The first 
drop of blood drawn was wiped off and discarded. Blood ketone levels were measured 
using a Precision Xtra Blood Glucose and Ketone Monitoring System (Abbott, Alameda, 
CA) with blood β-Ketone test strips. Blood glucose levels were measured using an 
AlphaTRAK Blood Glucose Monitoring System (Abbott Laboratories North Chicago, IL) 
with glucose test strips for rats and mice. Each rat’s blood glucose and ketones were 
measured and recorded with the time of day before the next rat was anesthetized and the 
process was repeated for the next rat. 
 
3.7 Statistical Analysis 
A two group comparison using students two way student’s t-test was used to analyze the 
data with statistical significance determined using the Holm-Sidak method, with alpha = 
5%. This was carried out in GraphPad Prism version 6.0 for mac OS X, GraphPad 
Software, San Diego California USA, www.graphpad.com.  
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3.8 Experimental Timeline 
Fig 1. Timeline of experiment  
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Chapter 4: Results 
4.1 Verification and Temporal Distribution of Seizures 
We first established that all MSO-infused rats developed recurrent seizures, i.e. ≥ 
2 seizures each separated by at least 1 h. An initial group of 18 standard chow (SC) 
control and 7 KD rats were studied for 21 days. A second group of 8 SC control and 5 
KD rats were studied for 35 days. All rats (38 of 38) were monitored by continuous video 
and hippocampal depth electrode EEG recordings, and all of the rats developed recurrent 
seizures. 
We then assessed the temporal distribution of the seizures. Thirty-three (87%) of 
the animals exhibited an initial cluster of recurrent seizures that began within the first 48 
h after the initiation of MSO infusion (Fig. 1). The highest mean frequency of seizures 
during the initial cluster was observed during days 1 (12.9 seizures per 24h, range = 0 to 
73) and 2 (9.8 seizures per 24h, range, 0 to 71 ; Fig. 2). Then during day 3 the seizure 
frequency began to decline markedly, from an average of 3.4 seizures per 24 h (range, 0 
to 50) to an average of 1 seizure per 24 h (range, 0 to 12) on day 4. After the initial 
cluster of seizures, on days 6 and 7 there was an increase in the mean number of seizure 
to 2.9 and 3.7 respectively, before declining again in an asymptotic manner towards zero. 
This distribution of seizures is similar to what has been seen before in previous studies 
using the MSO model.96 
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Figure 2. Overview of the temporal distribution of seizures. Thirty-eight animals were 
recorded by continuous video-intracranial  EEG: 26 on standard chow (SC) ad libitum, 
and 12 on a KD with 20% caloric restriction.  Seizure counts are given and the days when 
seizures occurred are highlighted in color. Note the presence of an initial cluster of very 
frequent seizures in most animals. Subsequent clusters of seizures occurred throughout 
the monitoring period. 
Animal Group Seizure/Count///24/hrs
VIII SC 21 23 1 1 0 0 0 0 2 2 1 1 2 3 2 2 2 0 4 1 2
IX SC 2 5 1 0 2 3 2 3 7 1 1 0 0 0 0 0 0 0 2 0 1
X SC 32 1 0 0 0 0 0 2 4 0 0 0 2 1 2 3 0 1 2 10 13
XI SC 73 71 34 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
XII SC 0 0 0 4 18 36 62 44 79 40 0 0 0 0 0 0 0 0 0 0 0
XIII SC 18 6 0 0 0 0 1 0 0 0 3 0 0 0 0 3 0 0 1 13 0
XIV SC 38 11 0 0 0 1 1 0 2 1 1 0 0 0 22 1 0 0 1 1 2
XV SC 0 49 5 0 0 0 0 0 0 0 3 4 1 0 0 3 3 1 5 2 1
XVI SC 5 6 0 3 0 2 3 1 2 0 1 1 1 1 2 0 1 0 2 0 1
XVII SC 3 5 0 0 1 1 2 2 1 2 2 0 4 1 1 2 2 1 2 1 1
XVIII SC 3 4 2 1 1 0 3 0 1 0 1 0 3 0 0 0 1 0 2 0 1
XIX SC 4 3 0 0 1 1 1 2 1 1 1 1 0 1 1 2 1 1 1 1 1
XX SC 6 5 2 0 1 2 0 3 1 0 1 0 0 0 0 0 0 0 0 0 0
XXI SC 2 12 1 1 3 2 1 1 0 0 1 0 1 0 0 1 1 1 0 1 0
XXII SC 11 16 0 0 6 4 1 2 2 1 1 1 1 0 1 1 0 1 0 1 1
XXIII SC 2 0 0 0 0 4 5 2 2 3 1 1 1 0 1 2 2 0 2 3 1
XXIV SC 11 2 8 5 4 1 0 0 1 1 1 0 0 2 0 0 1 0 0 0 0
XXV SC 6 5 0 0 0 0 5 0 1 0 1 0 0 0 0 1 0 0 2 0 1
XXXI SC 1 7 0 2 2 1 1 1 0 1 0 2 0 1 1 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0
XXXII SC 0 0 5 5 1 0 0 0 3 4 3 14 15 13 7 13 9 15 3 0 0 0 0 6 2 2 0 0 1 0 0 1 0 0 0
XXXIII SC 0 0 0 0 0 0 0 0 3 0 1 1 1 1 1 2 3 4 0 0 0 0 4 0 6 19 0 0 0 0 0 0 0 0 0
XXXIV SC 6 4 1 0 1 1 3 0 0 2 1 3 0 0 2 0 0 1 0 2 0 0 1 1 1 1 0 0 0 1 1 0 0 0 1
XXXV SC 19 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0
XXXVI SC 21 1 0 0 0 2 0 3 2 0 0 0 0 1 0 1 0 2 1 1 3 0 0 0 2 0 2 0 1 2 0 0 0 0 3
XXXVII SC 0 13 5 0 0 0 1 1 2 0 0 1 1 0 4 3 0 1 0 0 1 1 0 1 0 0 0 1 1 1 0 0 0 0 0
XXXVIII SC 66 3 1 0 0 0 0 1 0 1 1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 3 1 0 0 3 0 0 1 0
I KD 4 7 0 0 0 0 0 0 3 4 3 33 2 0 0 0 0 0 0 0 0
II KD 55 56 50 4 0 0 1 0 1 0 0 2 0 0 0 0 0 1 6 3 0
III KD 17 5 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 2 0 11 6
IV KD 0 2 0 0 0 0 0 2 9 1 0 0 0 0 1 1 1 1 0 0 0
V KD 42 24 0 0 0 0 1 2 2 2 2 1 1 5 5 4 1 1 2 2 0
VI KD 0 0 5 0 4 41 35 42 6 0 0 0 0 1 0 0 0 1 3 0 0
VII KD 0 9 3 0 0 0 0 1 2 1 4 1 0 1 0 0 2 1 8 3 4
XXVI KD 2 3 1 0 0 0 0 0 0 1 3 1 3 0 0 3 1 0 2 0 1 1 0 4 1 0 0 2 2 5 0 0 0 5 0
XXVII KD 13 3 0 0 2 3 2 2 0 0 2 1 2 1 0 0 0 1 0 1 0 0 2 0 0 1 0 0 1 0 0 1 0 1 3
XXVIII KD 0 0 0 12 1 0 3 4 3 2 1 1 1 1 1 1 0 1 0 1 1 1 1 1 0 0 0 0 0 1 1 0 0 0 1
XXIX KD 6 3 4 0 0 1 4 0 1 2 1 0 1 0 1 0 0 0 0 1 1 1 3 1 0 1 1 1 0 0 1 0 0 0 0
XXX KD 2 4 2 0 0 3 3 0 0 0 1 1 1 1 1 2 2 0 1 1 0 0 1 1 1 0 0 0 1 0 1 1 0 1 0
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Standard8Chow KD8began8on8day888for8KD8treatment8group
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Fig 3. Plot of the seizure frequency for all animals for the first seven days after MSO 
infusion. The line drawn through the boxes represents the average seizure frequency for 
that particular day.  Note the cluster of initial seizures during days 1-2, followed by a 
decline in seizure frequency during days 3-5, with subsequent smaller increase during 
days 6-7. 
 
 
Fig 4. Average number of seizures each day for both groups of animals. The greatest 
number of seizures for both groups occurred during the first 3 days of the study; there is a 
nadir around day 5, then another peak days 6-9, followed by a slow taper 
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4.2 Effect of KD on Seizure Frequency 
 
Next we evaluated the effect of the KD on the frequency of seizures in the MSO-
infused rats. This was done by binning the total number of seizures in intervals of 1 week 
followed by statistical analysis using a student’s t-test (Fig. 4a). Surgery was done on day 
0, and both groups (SC and KD) were fed a standard diet ad libitum during week 1 to 
facilitate recovery from surgery. A KD with 20% caloric restriction was initiated in the 
treatment group on week 2. An initial study was carried out for 3 weeks (with 7 KD and 
18 SC rats), and then a second study was carried out for 5 weeks (with 5 KD and 8 SC 
rats), accounting for the smaller N in the graphs during weeks 4 and 5. 
We found no significant difference in the weekly frequency of seizures in rats on 
the KD versus rats on SC (Table 3). During the first week, both groups had similar mean 
numbers of seizures (SC: 34.3 ± 7.6, KD: 36.8 ± 13.8), which would be expected because 
both groups were fed normal chow ad libitum.   Both groups continued to exhibit similar 
mean numbers of seizures during week 2 (SC: 13.8 ± 6.3, KD: 14.4 ± 4.6).  During weeks 
3 and 4, the KD group had 14% (1.3), and 32% (2.3) fewer mean number of seizures than 
the SC group, though the difference was not statistically significant (p=0.70, and p=0.61, 
respectively). During week 5, the KD group paradoxically had more seizures (SC: 2.1 ± 
0.8. KD: 5.2 ± 1.8), but again, this was not statistically significant (p=0.11). 
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 KD: mean # of all 
seizures ± SEM 
SC: mean # of all 
seizures ±SEM 
p-value 
Week 1 36.8 ± 13.8 34.3 ± 7.6 0.86 
Week 2 14.4 ± 4.6 13.8 ± 6.3 0.95 
Week 3 8.0 ± 1.9 9.3 ± 2.1 0.70 
Week 4 5.0 ± 1.2 7.3 ± 3.2 0.61 
Week 5 5.2 ± 1.8 2.1 ± 0.8 0.11 
Table 3. Comparison of the average number of seizures for KD vs. standard chow (SC) 
treated rats. The number of seizures were binned in one week intervals. During week 1, 
all rats are fed SC ad libitum. Treatment with the KD began during week 2.   Student’s t-
test showed no significant reduction of seizures in any week with statistical significance 
determined using the Holm-Sidak method, with alpha = 5%. 
 
4.3 Effect of KD on Seizure Severity 
 
 Next we evaluated the effect of the KD on the behavioral severity of seizures. 
This was done by examining the video record to stage the seizures, using a modification 
of Racine's criteria, as described in the methods. The weekly frequency of seizures at 
each of the behavioral stages was compared between the KD and SC treated rats  using a 
student’s t-test. 
 We found no significant difference in the severity of seizures between rats treated 
with the KD and rats fed SC (Fig. 4b-f. and Table 4) using student’s t-test with statistical 
significance determined using the Holm-Sidak method, with alpha = 5%. 
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Fig. 5. Weekly frequency of all seizure types (a) and of seizure types at different 
behavioral severities (b-f) in KD treated (blue bars) and standard chow (SC, red bars) 
rats.  All rats were given SC during week 1.  KD started on week 2.    Shown is the mean 
number of seizures. There were no significant differences in seizure frequency or severity 
between KD versus SC treated rats.     
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4.4 Table of Results for Seizure Severity 
For table 4 below, the number of seizures were sorted by severity and binned in one week 
intervals. During week 1 all rats are fed standard chow ad libitum. Treatment with the 
KD began during week 2. Shown below is the mean ± SEM number of seizures for each 
week and the corresponding p-value. Student’s t-test showed no significant reduction of 
seizures in any week with statistical significance determined using the Holm-Sidak 
method, with alpha = 5%. The p-value for stage 4 seizures during week 5 was p=0.02, 
however using the Holm-Sidak method of correcting for multiple comparisons, the values 
was not significant. 
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 KD: mean # of 
seizures ± SEM 
SC: mean # of  
seizures ± SEM 
p-value 
 Stage 1 Stage 1  
Week 1 21.5 ± 5.6 19.0 ± 2.9 0.66 
Week 2 7.2 ± 3.1 5.8 ± 2.4 0.74 
Week 3 2.9 ± 0.9 2.3 ± 0.8 0.67 
Week 4 0.2 ± 0.2 2.8 ± 1.4 0.16 
Week 5 0.2 ± 0.2 0.6 ± 0.3 0.36 
 Stage 2 Stage 2  
Week 1 2.4 ± 1.5 3.6 ± 1.3 0.60 
Week 2 0.8 ± 0.5 2.6 ± 2.0 0.57 
Week 3 0.4 ± 0.2 0.3 ± 0.2 0.59 
Week 4 0.8 ± 0.6 0.1 ± 0.1 0.18 
Week 5 0.2 ± 0.2 0.0 ± 0.0 0.22 
 Stage 3 Stage 3  
Week 1 1.5 ± 0.9 1.3 ± 0.3 0.81 
Week 2 0.8 ± 0.4 0.5 ± 0.2 0.52 
Week 3 0.3 ± 0.2 0.4 ± 0.2 0.62 
Week 4 0.4 ± 0.4 0.0 ± 0.0 0.23 
Week 5 0.0 ± 0.0 0.0 ± 0.0 n/a 
 Stage 4 Stage 4  
Week 1 2.1 ± 1.1 3.2 ± 1.5 0.63 
Week 2 1.1 ± 0.7 1.6 ± 0.7 0.66 
Week 3 1.5 ± 09 2.0 ± 0.7 0.67 
Week 4 2.0 ± 0.7 1.0 ± 0.4 0.21 
Week 5 1.2 ± 0.5 0.1 ± 0.4 0.02 
 Stage 5 Stage 5  
Week 1 8.2 ± 7.1 5.5 ± 2.6 0.65 
Week 2 3.7 ± 3.1 3.1 ± 1.3 0.84 
Week 3 2.3 ± 1.3 3.8 ± 0.9 0.32 
Week 4 1.4 ± 0.6 3.3 ± 2.0 0.50 
Week 5 2.6 ± 1.3  1.1 ± 0.4 0.22 
Table 4. Mean number of seizure for KD and SC rats sorted by severity.  
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4.5 Blood Glucose and Ketone Levels 
Blood glucose and ketone levels were measured throughout the experiment, starting on 
the day of surgery (day 0) in a random selection of rats. As can be seen from the graphs 
in Figure 5, prior to the start of the diet, both groups of rats had similar blood glucose and 
ketone levels (give values). The KD was started on day 8, and significant differences in 
blood glucose levels between the two groups were seen in measurements taken after the 
start of the diet (days 14, 21, 28). Significant differences in blood ketone levels are seen 
between the two groups in days 21 and 28. There were no measurements taken of ketone 
levels in the diet group on day 14. No blood glucose or ketone measurements were taken 
in standard chow rats on day 35 (Table 5) 
 
 
 
 
Figure 6. Blood glucose and ketone levels for a random selection of 8 rats in the KD and 
SC treated groups. Both groups were fed standard chow ad libitum for 7 days to facilitate 
recovery from surgery. The diet group started treatment on day 8. The first measurement 
taken while the rats were on the KD was on day 14. KD rats had significantly decreased 
blood glucose levels on days 14, 21, and 28. KD rats had significantly increased blood 
ketone levels on days 21 and 28. 
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 KD: Mean Blood 
Glucose Levels 
mg/dL ± SEM 
SC: Mean  Blood 
Glucose Levels 
mg/dL ± SEM 
p-value 
Day 0 133 ± 5.9 151 ± 7.5 0.08 
Day 7 138 ± 5.6 140 ± 5.0 0.91 
Day 14 116 ± 5.8 137 ± 3.4 0.005* 
Day 21 111 ± 2.7 139 ± 7.0 0.004* 
Day 28 114 ± 3.2 132 ± 5.8 0.019* 
Day 35 113 ± 6.7 No Data N/A 
Table 5. Mean blood glucose levels for KD and SC rats. Significant differences are 
marked with and asterisk. 
 KD: Mean Blood 
Ketone Levels 
mm/dL ± SEM 
SC: Mean Blood 
Ketone Levels 
mm/dL ± SEM 
p-value 
Day 0 0.39 ± 0.05 0.38 ± 0.06 0.87 
Day 7 0.38 ± 0.06 0.26 ± 0.03 0.10 
Day 14 No Data 0.33 ± 0.03 N/A 
Day 21 1.04 ± 0.10 0.36 ± 0.03 < 0.0001* 
Day 28 0.97 ± 0.04 0.39 ± 0.05  <0.0001* 
Day 35 1.17 ± 0.07 No Data N/A 
Table 6. Mean blood ketone levels for KD and SC rats. Significant differences are 
marked with an asterisk. 
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Chapter 5: Discussion 
TLE is a particular devastating form of epilepsy. It is often drug resistant despite 
treatment with appropriate anti-epileptic drugs. Due to the unpredictable timing of 
seizures in this disease, patient with uncontrolled epilepsy experience a decreased quality 
of life with significant psychological, economical, and social impact. Thus, there is a 
need for greater understanding of the pathophysiology of TLE and a necessity to develop 
more efficacious therapies for this disease.  
The KD was developed in the 1920s, after observation that fasting decreased 
seizures in some patients, and before the first truly effective AED, phenytoin, was 
discovered. Since the discovery of phenytoin there have been many new AEDs come on 
the market, yet up to 25% of all adults with epilepsy, and 40% of patients with TLE have 
uncontrolled seizures, despite treatment with multiple drugs97. Lack of effective drugs 
has led to a renewed interest in the KD as a treatment for refractory seizures. The KD is a 
high-fat, low carbohydrate diet that has been shown in randomized controlled trials to be 
effective in reducing seizure burden in patients with refractory epilepsy55.  
In this study we examined the effects of the KD on a highly relevant rat model of 
TLE.  Continuous infusion of MSO, an inhibitor of glutamine synthetase, unilaterally into 
the hippocampus in rats consistently results in episodes of recurrent, mainly partial 
seizures, as shown here and in earlier studies96. This model also produces 
neuropathological changes seen in human TLE, such as hippocampal sclerosis and 
selective loss of MCT1 on microvessels in the hippocampus.87 
The general trend of seizures for both the SC and KD treated rats showed the 
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greatest number of seizures occurring during the first 3 days of the study; there is a nadir 
around day 5, then another peak days 6-9, followed by a slow taper. There is a trend 
towards the development of more severe seizures as time goes on. That is, the majority of 
seizures during the first week are stage 1 events. By week 5, however, the majority of 
seizures are stage 4 and 5. We found no significant difference in the number or severity 
of seizures between the two groups in this study. 
Why was the KD ineffective in this trial? Despite relatively strong evidence of the 
effectiveness of the KD in humans, evidence of the effectiveness of the KD in animal 
models is much less robust – results have been model dependent, age dependent, and 
occasionally contradictory. The first animal study to look at prolonged treatment with the 
KD was done by Uhlemann and Neims in 1972 on mice, using a number of different 
techniques to induce seizures.98 They found that a 3:1 KD (70% fat) protected mice from 
bicuculline, maximum electroshock and hydration electroshock seizures, but not against 
threshold electroshock or pentylenetetrazole induced seizures. They also found that the 
diet had an anticonvulsive effect only in neonatal mice. This is similar to the results of 
other studies that have found an age dependent effect of the KD in animal models.99  
Mahoney et al found that magnesium deficient, audiogenic-induced seizure rats 
treated with the KD surprisingly had increased seizure severity and decreased seizure 
latency.100 In another paradoxical result, 20 day old rat pups weaned on a medium chain 
triglyceride diet for 10 day before they were subjected to maximum electroshock, 
threshold electroconvulsive shock, threshold pentylenetetrazole, or maximum 
pentylenetetrazole, no protective effect of the KD was observed; and the KD was actually 
proconvulsant in tests involving maximal seizure, despite blood levels of BHB that were 
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comparable or higher to those commonly reported in clinical studies.101  
In a similar study comparing the effectiveness of the KD in threshold seizure tests 
(pentylenetetrazol infusion test and the electroconvulsive shock test threshold test) to 
suprathreshold seizure tests (maximal pentylenetetrazol test and maximal electroshock 
test) and found KD was ineffective in reducing seizures in suprathreshold test, but did 
reduce seizures, albeit slightly, in threshold test.102 The authors posit that the KD 
produces a small elevation in seizure threshold and only works when the stimulus does 
not greatly exceed the seizure threshold. The end result of these studies is that we still do 
not have a clear picture when or how the diet works in animal models, but results seem to 
be sporadic and dependent upon a number of factors. Bough and Rho, reviewing the 
literature of animal studies using the KD, came away with the following generalizations: 
the anticonvulsant effects in rats and mice is much more moderate than in humans (15-
20% reduction in animals compared to >50% reduction in most human trials); the 
anticonvulsant effects of the KD are incomplete and of limited duration in many animal 
studies; the KD does not seem to diminish severity once seizure have began, and may 
even exacerbate them, owing to increased energy stores as a result of the KD.103 These 
generalizations are similar to what we observed in this study. Therefore the lack of effect 
of the KD might be due to the limited efficacy in rat models overall - in which the current 
MSO rat study is included. 
Another possible explanation might be that the KD is effective in some types of 
refractory epilepsies, but not in TLE. At the Mayo clinic the diet was traditionally 
thought to be useful only in the treatment of “idiopathic” epilepsies.104 This was based on 
clinical experience of the author, and he gives no evidence to support why this would be 
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the case. But finding definitive evidence of the KD in the treatment of TLE is a 
challenge, as most data come from patients with generalized seizures. In a trial of the 
efficacy of the KD in generalized versus focal seizures, the diet was found to be equally 
effective in both.59 However, only 34 focal patients were included in the study (compared 
to 100 generalized), outcomes tended to be better in younger patients, and focal 
epilepsies were not further delineated into subtypes. In the pediatric randomized control 
trial of the KD, 57 children had focal epilepsy (27 with structural abnormalities, 16 
“presumed focal”, and 14 multifocal) and the KD was as effective for them as it was for 
patients with generalized epilepsy.55 No patient subgoups of TLE were identified 
however, so it is hard to extrapolate these results specifically to TLE. 
Another factor to take into consideration is that a lack of significant difference 
does not rule out the presence of a real, but small difference that cannot be detected due 
to the statistical power of the present study. With alpha = 0.05, beta ≥ 0.8, a 30% 
expected reduction in seizures, a standard deviation of 125%, and a two group 
comparison using a two-way student’s t-test, a minimum number of n = 16 animals per 
group is required to detect a therapeutic effect. With our N of 12 KD animals, we are 
slightly below this number so it is possible that the KD is having an effect, it is just not 
detectable with the present number of animals.  
One of the barriers to more widespread use of the KD, especially in adults is 
tolerability of the diet. While it is relatively easy to initiate the diet in infants and small 
children, few adolescents or adults are willing to cut carbohydrates completely out of 
their diet.  Dietary guidelines must be followed strictly, however, for the diet to be 
effective and breaking ketosis diminishes the therapeutic effect of the diet almost 
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immediately.  
The idea of food as therapy has been with us since antiquity, but one of the most 
dramatic examples was the ingestion of large amounts of liver to treat pernicious anemia, 
a previously fatal disease. Murphy, during his Nobel lecture in 1934 for, “Discoveries 
Concerning Liver Therapy in Cases of Anemia” said, “... [a] problem which, during the 
past few years, has particularly interested me, as a practitioner of medicine, has been the 
practical one of making treatment more bearable for the victim... who must necessarily 
continue treatment indefinitely in order to maintain a satisfactory state of health”.105 This 
remains a laudable goal today and is particularly relevant to patients with intractable 
epilepsy on a ketogenic diet who must eat an exorbitant amount of fat while strictly 
limiting carbohydrate intake. 
Distilling the essential aspects of the KD into a more bearable treatment will 
require an understanding of the mechanism of action of the diet. We are getting closer to 
an understanding, but we still do not know how the diet works. Further exploration, 
perhaps with different animal models will be needed to flesh this out. The KD was 
unsuccessful in this study, but there is good evidence that it is effective in humans, 
especially children with drug resistant epilepsy. Perhaps further research into the diet will 
yield novel treatments for those who need it most. 
 
 
 
41	  
References 
1	   Hauser,	  W.	  A.	  &	  Hesdorffer,	  D.	  C.	  Epilepsy:	  frequency,	  causes,	  and	  
consequences.	  	  (Epilepsy	  Foundation	  of	  America,	  1990).	  2	   Spencer,	  D.	  D.,	  Spencer,	  S.	  S.,	  Mattson,	  R.	  H.,	  Williamson,	  P.	  D.	  &	  Novelly,	  R.	  A.	  Access	  to	  the	  posterior	  medial	  temporal	  lobe	  structures	  in	  the	  surgical	  treatment	  of	  temporal	  lobe	  epilepsy.	  Neurosurgery	  15,	  667	  (1984).	  3	   Kwan,	  P.	  &	  Brodie,	  M.	  J.	  Early	  identification	  of	  refractory	  epilepsy.	  New	  
England	  Journal	  of	  Medicine	  342,	  314	  (2000).	  4	   Baker,	  G.	  A.,	  Jacoby,	  A.,	  Buck,	  D.,	  Stalgis,	  C.	  &	  Monnet,	  D.	  Quality	  of	  life	  of	  people	  with	  epilepsy:	  a	  European	  study.	  Epilepsia	  38,	  353-­‐362	  (1997).	  5	   Holmes,	  G.	  L.	  Seizure-­‐induced	  neuronal	  injury:	  animal	  data.	  Neurology	  59,	  3	  (2002).	  6	   Wilder,	  R.	  M.	  in	  Mayo	  Clin	  Proc.	  	  307-­‐308.	  7	   Pan,	  J.	  W.,	  Bebin,	  E.	  M.,	  Chu,	  W.	  J.	  &	  Hetherington,	  H.	  P.	  Ketosis	  and	  epilepsy:	  31P	  spectroscopic	  imaging	  at	  4.1	  T.	  Epilepsia	  40,	  703-­‐707	  (1999).	  8	   Hartman,	  A.	  L.	  Does	  the	  effectiveness	  of	  the	  ketogenic	  diet	  in	  different	  epilepsies	  yield	  insights	  into	  its	  mechanisms?	  Epilepsia	  49,	  53-­‐56	  (2008).	  9	   Bough,	  K.	  J.,	  Valiyil,	  R.,	  Han,	  F.	  T.	  &	  Eagles,	  D.	  A.	  Seizure	  resistance	  is	  dependent	  upon	  age	  and	  calorie	  restriction	  in	  rats	  fed	  a	  ketogenic	  diet.	  
Epilepsy	  research	  35,	  21-­‐28	  (1999).	  10	   Meyer,	  A.	  C.	  et	  al.	  Critical	  determinants	  of	  the	  epilepsy	  treatment	  gap:	  a	  cross-­‐national	  analysis	  in	  resource-­‐limited	  settings.	  Epilepsia	  53,	  2178-­‐2185,	  doi:10.1111/epi.12002	  (2012).	  11	   Fisher,	  R.	  S.	  et	  al.	  Epileptic	  seizures	  and	  epilepsy:	  definitions	  proposed	  by	  the	  International	  League	  Against	  Epilepsy	  (ILAE)	  and	  the	  International	  Bureau	  for	  Epilepsy	  (IBE).	  Epilepsia	  46,	  470-­‐472,	  doi:10.1111/j.0013-­‐9580.2005.66104.x	  (2005).	  12	   Proposal	  for	  revised	  classification	  of	  epilepsies	  and	  epileptic	  syndromes.	  
Epilepsia	  30,	  389-­‐399	  (1989).	  13	   Proposal	  for	  revised	  clinical	  and	  electroencephalographic	  classification	  of	  epileptic	  seizures.	  From	  the	  Commission	  on	  Classification	  and	  Terminology	  of	  the	  International	  League	  Against	  Epilepsy.	  Epilepsia	  22,	  489-­‐501	  (1981).	  14	   Tellez-­‐Zenteno,	  J.	  F.	  &	  Hernandez-­‐Ronquillo,	  L.	  A	  review	  of	  the	  epidemiology	  of	  temporal	  lobe	  epilepsy.	  Epilepsy	  research	  and	  treatment	  2012,	  630853,	  doi:10.1155/2012/630853	  (2012).	  15	   Hauser,	  W.	  A.	  &	  Kurland,	  T.	  The	  epidemiology	  of	  epilepsy	  in	  Rochester,	  Minnesota,	  1935	  through	  1967.	  Epilepsia	  16,	  1-­‐66	  (1975).	  16	   Wiebe,	  S.,	  Blume,	  W.	  T.,	  Girvin,	  J.	  P.	  &	  Eliasziw,	  M.	  A	  randomized,	  controlled	  trial	  of	  surgery	  for	  temporal-­‐lobe	  epilepsy.	  New	  England	  Journal	  of	  Medicine	  
345,	  311	  (2001).	  17	   De	  Lanerolle,	  N.	  C.	  et	  al.	  A	  Retrospective	  Analysis	  of	  Hippocampal	  Pathology	  in	  Human	  Temporal	  Lobe	  Epilepsy:	  Evidence	  for	  Distinctive	  Patient	  Subcategories.	  Epilepsia	  44,	  677-­‐687	  (2003).	  
42	  
18	   Sutula,	  T.,	  Cascino,	  G.,	  Cavazos,	  J.,	  Parada,	  I.	  &	  Ramirez,	  L.	  Mossy	  Fiber	  Synaptic	  Reorganization	  in	  the	  Epileptic	  Human	  Temporal	  Lobe.	  Annals	  of	  
Neurology	  26,	  322-­‐330	  (1989).	  19	   de	  Lanerolle,	  N.	  C.	  et	  al.	  Neurochemical	  remodelling	  of	  the	  hippocampus	  in	  human	  temporal	  lobe	  epilepsy.	  Epilepsy	  research.	  Supplement	  9,	  205-­‐219-­‐	  discussion	  220	  (1992).	  20	   French,	  J.	  A.	  et	  al.	  Characteristics	  of	  Medial	  Temporal	  Lobe	  Epilepsy:	  I.	  Results	  of	  History	  and	  Physical	  Examination.	  Annals	  of	  Neurology	  34,	  774-­‐780	  (1993).	  21	   Cendes,	  F.	  et	  al.	  Early	  childhood	  prolonged	  febrile	  convulsions,	  atrophy	  and	  sclerosis	  of	  mesial	  structures,	  and	  temporal	  lobe	  epilepsy:	  An	  MRI	  volumetric	  study.	  Neurology	  43,	  1083-­‐1083,	  doi:10.1212/wnl.43.6.1083	  (1993).	  22	   Mathern,	  G.,	  Babb,	  T.,	  Vickrey,	  B.,	  Melendez,	  M.	  &	  Pretorius,	  K.	  The	  clinical-­‐pathogenic	  mechanisms	  of	  hippocampal	  neuron	  loss	  and	  surgical	  outcomes	  in	  temporal	  lobe	  epilepsy.	  Brain	  118,	  105-­‐118	  (1995).	  23	   Meldrum,	  B.	  S.	  Glutamate	  as	  a	  Neurotransmitter	  in	  the	  Brain:	  Review	  of	  Physiology	  and	  Pathology.	  Journal	  of	  Nutrition	  130,	  1007-­‐1015	  (2000).	  24	   Lajtha,	  A.,	  Berl,	  S.	  &	  Waelsch,	  H.	  AMINO	  ACID	  AND	  PROTEIN	  METABOLISM	  OF	  THE	  BRAIN—IV.	  Journal	  of	  neurochemistry	  3,	  322-­‐332	  (1959).	  25	   Cavus,	  I.	  et	  al.	  Extracellular	  metabolites	  in	  the	  cortex	  and	  hippocampus	  of	  epileptic	  patients.	  Annals	  of	  Neurology	  57,	  226-­‐235	  (2005).	  26	   Petroff,	  O.	  A.,	  Errante,	  L.	  D.,	  Kim,	  J.	  H.	  &	  Spencer,	  D.	  D.	  N-­‐acetyl-­‐aspartate,	  total	  creatine,	  and	  myo-­‐inositol	  in	  the	  epileptogenic	  human	  hippocampus.	  
Neurology	  60,	  1646-­‐1651	  (2003).	  27	   Petroff,	  O.,	  Cavus,	  I.,	  Kim,	  J.	  &	  Spencer,	  D.	  Interictal	  extracellular	  glutamate	  concentrations	  are	  increased	  in	  hippocampal	  sclerosis.	  Ann	  Neurol	  56,	  S43	  (2004).	  28	   Kim,	  J.	  H.	  et	  al.	  Hippocampal	  glial	  density	  in	  temporal	  lobe	  epilepsy.	  Epilepsia	  
45,	  S33-­‐S34	  (2004).	  29	   During,	  M.	  &	  Spencer,	  D.	  Extracellular	  hippocampal	  glutamate	  and	  spontaneous	  seizure	  in	  the	  conscious	  human	  brain.	  The	  lancet	  341,	  1607-­‐1610	  (1993).	  30	   Petroff,	  O.	  A.,	  Errante,	  L.	  D.,	  Rothman,	  D.	  L.,	  Kim,	  J.	  H.	  &	  Spencer,	  D.	  D.	  Glutamate–glutamine	  cycling	  in	  the	  epileptic	  human	  hippocampus.	  Epilepsia	  
43,	  703-­‐710	  (2002).	  31	   Olney,	  J.	  W.,	  SHARPE,	  L.	  G.	  &	  FEIGIN,	  R.	  D.	  Glutamate-­‐induced	  brain	  damage	  in	  infant	  primates.	  Journal	  of	  Neuropathology	  &	  Experimental	  Neurology	  31,	  464	  (1972).	  32	   Eid,	  T.	  et	  al.	  Loss	  of	  glutamine	  synthetase	  in	  the	  human	  epileptogenic	  hippocampus:	  possible	  mechanism	  for	  raised	  extracellular	  glutamate	  in	  mesial	  temporal	  lobe	  epilepsy.	  The	  lancet	  363,	  28-­‐37	  (2004).	  33	   Wang,	  Y.	  et	  al.	  Inhibition	  of	  hippocampal	  glutamine	  synthetase	  causes	  spontaneously	  recurrent	  seizures	  in	  rats.	  Epilepsia	  47	  (2006).	  34	   Eid,	  T.	  et	  al.	  Recurrent	  seizures	  and	  brain	  pathology	  after	  inhibition	  of	  glutamine	  synthetase	  in	  the	  hippocampus	  in	  rats.	  Brain	  131,	  2061	  (2008).	  
43	  
35	   Eid,	  T.,	  Williamson,	  A.,	  Lee,	  T.	  S.	  W.,	  Petroff,	  O.	  A.	  &	  De	  Lanerolle,	  N.	  C.	  Glutamate	  and	  astrocytes—Key	  players	  in	  human	  mesial	  temporal	  lobe	  epilepsy?	  Epilepsia	  49,	  42-­‐52	  (2008).	  36	   Shank,	  R.	  P.,	  Bennett,	  G.	  S.,	  Freytag,	  S.	  O.	  &	  Campbell,	  G.	  L.	  Pyruvate	  carboxylase:	  an	  astrocyte-­‐specific	  enzyme	  implicated	  in	  the	  replenishment	  of	  amino	  acid	  neurotransmitter	  pools.	  Brain	  research	  329,	  364-­‐367	  (1985).	  37	   Martinez-­‐Hernandez,	  A.,	  Bell,	  K.	  P.	  &	  Norenberg,	  M.	  D.	  Glutamine	  synthetase:	  glial	  localization	  in	  brain.	  Science	  (New	  York,	  NY)	  195,	  1356	  (1977).	  38	   Svenneby,	  G.	  Pig	  brain	  glutaminase:	  purification	  and	  identification	  of	  different	  enzyme	  forms.	  Journal	  of	  neurochemistry	  17,	  1591-­‐1599	  (1970).	  39	   Kvamme,	  E.,	  Torgner,	  I.	  A.	  &	  Roberg,	  B.	  Kinetics	  and	  localization	  of	  brain	  phosphate	  activated	  glutaminase.	  Journal	  of	  neuroscience	  research	  66,	  951-­‐958	  (2001).	  40	   Schwartz,	  R.	  D.	  The	  GABA-­‐A	  Receptor-­‐Gated	  Ion	  Channel:	  BIochemical	  and	  Pharmacological	  Studies	  of	  Structure	  and	  Funtion.	  Biochemical	  Pharmacology	  
37,	  3369-­‐3375	  (1988).	  41	   During,	  M.	  J.,	  Ryder,	  K.	  M.	  &	  Spencer,	  D.	  D.	  Hippocampal	  GABA	  transporter	  function	  in	  temporal-­‐lobe	  epilepsy.	  	  (1995).	  42	   Garty,	  R.,	  Yonis,	  Z.,	  Braham,	  J.	  &	  Steinitz,	  K.	  Pyridoxine-­‐dependent	  convulsions	  in	  an	  infant.	  Archives	  of	  disease	  in	  childhood	  37,	  21-­‐24	  (1962).	  43	   Horton,	  R.,	  Prestwich,	  S.	  &	  Meldrum,	  B.	  γ‐Aminobutyric	  Acid	  and	  Benzodiazepine	  Binding	  Sites	  in	  Audiogenic	  Seizure‐Susceptible	  Mice.	  
Journal	  of	  neurochemistry	  39,	  864-­‐870	  (2006).	  44	   Olsen,	  R.	  et	  al.	  Midbrain	  GABA	  receptor	  deficit	  in	  genetic	  animal	  models	  of	  epilepsy.	  Neurotransmitters,	  Seizures,	  and	  Epilepsy	  3,	  279-­‐291	  (1986).	  45	   Dubé,	  C.	  M.,	  Brewster,	  A.	  L.,	  Richichi,	  C.,	  Zha,	  Q.	  &	  Baram,	  T.	  Z.	  Fever,	  febrile	  seizures	  and	  epilepsy.	  Trends	  in	  neurosciences	  30,	  490-­‐496	  (2007).	  46	   Rasmussen,	  T.,	  Olszewski,	  J.	  &	  Lloyd-­‐Smith,	  D.	  Focal	  seizures	  due	  to	  chronic	  localized	  encephalitis.	  Neurology	  8,	  435-­‐435	  (1958).	  47	   Riikonen,	  R.	  Topical	  review:	  infantile	  spasms:	  therapy	  and	  outcome.	  Journal	  
of	  child	  neurology	  19,	  401-­‐404	  (2004).	  48	   Wheless,	  J.	  W.,	  Clarke,	  D.	  F.,	  Arzimanoglou,	  A.	  &	  Carpenter,	  D.	  Treatment	  of	  pediatric	  epilepsy:	  European	  expert.	  Epileptic	  Disord	  9,	  353	  (2007).	  49	   Vezzani,	  A.	  &	  Granata,	  T.	  Brain	  inflammation	  in	  epilepsy:	  experimental	  and	  clinical	  evidence.	  Epilepsia	  46,	  1724-­‐1743	  (2005).	  50	   De	  Simoni,	  M.	  G.	  et	  al.	  Inflammatory	  cytokines	  and	  related	  genes	  are	  induced	  in	  the	  rat	  hippocampus	  by	  limbic	  status	  epilepticus.	  European	  Journal	  of	  
Neuroscience	  12,	  2623-­‐2633	  (2001).	  51	   Vezzani,	  A.,	  French,	  J.,	  Bartfai,	  T.	  &	  Baram,	  T.	  Z.	  The	  role	  of	  inflammation	  in	  epilepsy.	  Nature	  Reviews	  Neurology	  7,	  31-­‐40	  (2010).	  52	   Xiong,	  Z.-­‐Q.,	  Qian,	  W.,	  Suzuki,	  K.	  &	  McNamara,	  J.	  O.	  Formation	  of	  complement	  membrane	  attack	  complex	  in	  mammalian	  cerebral	  cortex	  evokes	  seizures	  and	  neurodegeneration.	  The	  Journal	  of	  neuroscience	  23,	  955-­‐960	  (2003).	  53	   Swink,	  T.	  D.,	  Vining,	  E.	  &	  Freeman,	  J.	  M.	  The	  ketogenic	  diet:	  1997.	  Advances	  in	  
pediatrics	  44,	  297	  (1997).	  
44	  
54	   Freeman,	  J.	  M.	  et	  al.	  The	  efficacy	  of	  the	  ketogenic	  diet-­‐-­‐-­‐1998:	  a	  prospective	  evaluation	  of	  intervention	  in	  150	  children.	  Pediatrics	  102,	  1358	  (1998).	  55	   Neal,	  E.	  G.	  et	  al.	  The	  ketogenic	  diet	  for	  the	  treatment	  of	  childhood	  epilepsy:	  a	  randomised	  controlled	  trial.	  Lancet	  neurology	  7,	  500-­‐506	  (2008).	  56	   Freeman,	  J.	  M.	  &	  Vining,	  E.	  P.	  Seizures	  decrease	  rapidly	  after	  fasting:	  preliminary	  studies	  of	  the	  ketogenic	  diet.	  Archives	  of	  Pediatrics	  &	  Adolescent	  
Medicine	  153,	  946	  (1999).	  57	   Haas,	  R.	  H.	  et	  al.	  Therapeutic	  effects	  of	  a	  ketogenic	  diet	  in	  rett	  syndrome.	  
American	  Journal	  of	  Medical	  Genetics	  25,	  225-­‐246,	  doi:10.1002/ajmg.1320250525	  (1986).	  58	   Kossoff,	  E.	  H.	  &	  Hartman,	  A.	  L.	  Ketogenic	  diets:	  new	  advances	  for	  metabolism-­‐based	  therapies.	  Current	  Opinion	  in	  Neurology	  25,	  173-­‐178	  (2012).	  59	   Maydell,	  B.	  V.	  et	  al.	  Efficacy	  of	  the	  ketogenic	  diet	  in	  focal	  versus	  generalized	  seizures.	  Pediatric	  neurology	  25,	  208	  (2001).	  60	   Than,	  K.	  D.	  et	  al.	  Can	  you	  predict	  an	  immediate,	  complete,	  and	  sustained	  response	  to	  the	  ketogenic	  diet?	  Epilepsia	  46,	  580-­‐582	  (2005).	  61	   Kossoff,	  E.	  H.,	  Rowley,	  H.,	  Sinha,	  S.	  R.	  &	  Vining,	  E.	  P.	  A	  prospective	  study	  of	  the	  modified	  Atkins	  diet	  for	  intractable	  epilepsy	  in	  adults.	  Epilepsia	  49,	  316-­‐319	  (2007).	  62	   Marsh,	  E.	  B.	  et	  al.	  The	  Outcome	  of	  Children	  with	  Intractable	  Seizures:	  A	  3‐to	  6‐Year	  Follow‐up	  of	  67	  Children	  Who	  Remained	  on	  the	  Ketogenic	  Diet	  Less	  Than	  One	  Year.	  Epilepsia	  47,	  425-­‐430	  (2006).	  63	   Sirven,	  J.	  et	  al.	  The	  ketogenic	  diet	  for	  intractable	  epilepsy	  in	  adults:	  preliminary	  results.	  Epilepsia	  40,	  1721-­‐1726	  (2005).	  64	   Peterman,	  M.	  The	  ketogenic	  diet	  in	  the	  treatment	  of	  epilepsy:	  a	  preliminary	  report.	  Archives	  of	  Pediatrics	  &	  Adolescent	  Medicine	  28,	  28	  (1924).	  65	   Vining,	  E.	  P.	  et	  al.	  A	  multicenter	  study	  of	  the	  efficacy	  of	  the	  ketogenic	  diet.	  
Archives	  of	  neurology	  55,	  1433	  (1998).	  66	   Freeman,	  J.	  M.,	  Kossoff,	  E.	  H.	  &	  Hartman,	  A.	  L.	  The	  ketogenic	  diet:	  one	  decade	  later.	  Pediatrics	  119,	  535	  (2007).	  67	   Kwiterovich	  Jr,	  P.	  O.,	  Vining,	  E.	  P.,	  Pyzik,	  P.,	  Skolasky	  Jr,	  R.	  &	  Freeman,	  J.	  M.	  Effect	  of	  a	  high-­‐fat	  ketogenic	  diet	  on	  plasma	  levels	  of	  lipids,	  lipoproteins,	  and	  apolipoproteins	  in	  children.	  JAMA:	  the	  journal	  of	  the	  American	  Medical	  
Association	  290,	  912-­‐920	  (2003).	  68	   Patel,	  A.,	  Pyzik,	  P.	  L.,	  Turner,	  Z.,	  Rubenstein,	  J.	  E.	  &	  Kossoff,	  E.	  H.	  Long‐term	  outcomes	  of	  children	  treated	  with	  the	  ketogenic	  diet	  in	  the	  past.	  Epilepsia	  51,	  1277-­‐1282	  (2010).	  69	   Sampath,	  A.,	  Kossoff,	  E.	  H.,	  Furth,	  S.	  L.,	  Pyzik,	  P.	  L.	  &	  Vining,	  E.	  P.	  Kidney	  stones	  and	  the	  ketogenic	  diet:	  risk	  factors	  and	  prevention.	  Journal	  of	  child	  
neurology	  22,	  375-­‐378	  (2007).	  70	   Furth,	  S.	  L.	  et	  al.	  Risk	  factors	  for	  urolithiasis	  in	  children	  on	  the	  ketogenic	  diet.	  
Pediatric	  nephrology	  15,	  125-­‐128	  (2000).	  71	   Vining,	  E.	  P.	  et	  al.	  Growth	  of	  children	  on	  the	  ketogenic	  diet.	  Developmental	  
Medicine	  &	  Child	  Neurology	  44,	  796-­‐802	  (2007).	  
45	  
72	   Groesbeck,	  D.	  K.,	  Bluml,	  R.	  M.	  &	  Kossoff,	  E.	  H.	  Long‐term	  use	  of	  the	  ketogenic	  diet	  in	  the	  treatment	  of	  epilepsy.	  Developmental	  Medicine	  &	  Child	  Neurology	  
48,	  978-­‐981	  (2006).	  73	   Liu,	  T.,	  Megan,	  P.,	  Campbell,	  K.	  &	  Curtis,	  R.	  A	  retrospective	  study:	  growth	  status	  of	  children	  with	  epilepsy	  post	  treatment	  with	  the	  ketogenic	  diet.	  
Epilepsia	  46,	  155	  (2005).	  74	   Veech,	  R.	  L.	  The	  therapeutic	  implications	  of	  ketone	  bodies:	  the	  effects	  of	  ketone	  bodies	  in	  pathological	  conditions:	  ketosis,	  ketogenic	  diet,	  redox	  states,	  insulin	  resistance,	  and	  mitochondrial	  metabolism.	  Prostaglandins	  
Leukotrienes	  and	  Essential	  Fatty	  Acids	  70,	  309-­‐320	  (2004).	  75	   Huttenlocher,	  P.	  R.	  Ketonemia	  and	  seizures:	  metabolic	  and	  anticonvulsant	  effects	  of	  two	  ketogenic	  diets	  in	  childhood	  epilepsy.	  Pediatric	  research	  10,	  536-­‐540	  (1976).	  76	   Gilbert,	  D.	  L.,	  Pyzik,	  P.	  L.	  &	  Freeman,	  J.	  M.	  The	  ketogenic	  diet:	  seizure	  control	  correlates	  better	  with	  serum	  β-­‐hydroxybutyrate	  than	  with	  urine	  ketones.	  
Journal	  of	  child	  neurology	  15,	  787-­‐790	  (2000).	  77	   Rho,	  J.	  M.,	  Anderson,	  G.	  D.,	  Donevan,	  S.	  D.	  &	  White,	  H.	  S.	  Acetoacetate,	  Acetone,	  and	  Dibenzylamine	  (a	  Contaminant	  in	  l‐(+)‐β‐Hydroxybutyrate)	  Exhibit	  Direct	  Anticonvulsant	  Actions	  in	  Vivo.	  Epilepsia	  43,	  358-­‐361	  (2002).	  78	   Juge,	  N.	  et	  al.	  Metabolic	  control	  of	  vesicular	  glutamate	  transport	  and	  release.	  
Neuron	  68,	  99-­‐112	  (2010).	  79	   Devivo,	  D.	  C.,	  Leckie,	  M.	  P.,	  Ferrendelli,	  J.	  S.	  &	  McDougal,	  D.	  B.	  Chronic	  ketosis	  and	  cerebral	  metabolism.	  Annals	  of	  Neurology	  3,	  331-­‐337,	  doi:10.1002/ana.410030410	  (1978).	  80	   Mercer,	  R.	  W.	  &	  Dunham,	  P.	  B.	  Membrane-­‐bound	  ATP	  fuels	  the	  Na/K	  pump.	  Studies	  on	  membrane-­‐bound	  glycolytic	  enzymes	  on	  inside-­‐out	  vesicles	  from	  human	  red	  cell	  membranes.	  The	  Journal	  of	  General	  Physiology	  78,	  547-­‐568	  (1981).	  81	   Haller,	  M.,	  Mironov,	  S.,	  Karschin,	  A.	  &	  Richter,	  D.	  Dynamic	  activation	  of	  KATP	  channels	  in	  rhythmically	  active	  neurons.	  The	  Journal	  of	  physiology	  537,	  69-­‐81	  (2004).	  82	   Yellen,	  G.	  Ketone	  bodies,	  glycolysis,	  and	  KATP	  channels	  in	  the	  mechanism	  of	  the	  ketogenic	  diet.	  Epilepsia	  49,	  80-­‐82	  (2008).	  83	   Gimenez-­‐Cassina,	  A.	  et	  al.	  BAD-­‐dependent	  regulation	  of	  fuel	  metabolism	  and	  K(ATP)	  channel	  activity	  confers	  resistance	  to	  epileptic	  seizures.	  Neuron	  74,	  719-­‐730,	  doi:10.1016/j.neuron.2012.03.032	  (2012).	  84	   Danial,	  N.	  N.	  et	  al.	  Dual	  role	  of	  proapoptotic	  BAD	  in	  insulin	  secretion	  and	  beta	  cell	  survival.	  Nature	  medicine	  14,	  144-­‐153	  (2008).	  85	   Leino,	  R.	  L.,	  Gerhart,	  D.	  Z.,	  Duelli,	  R.,	  Enerson,	  B.	  E.	  &	  Drewes,	  L.	  R.	  Diet-­‐induced	  ketosis	  increases	  monocarboxylate	  transporter	  (MCT1)	  levels	  in	  rat	  brain.	  Neurochemistry	  international	  38,	  519-­‐527	  (2001).	  86	   Fischer,	  W.,	  Praetor,	  K.,	  Metzner,	  L.,	  Neubert,	  R.	  H.	  H.	  &	  Brandsch,	  M.	  Transport	  of	  valproate	  at	  intestinal	  epithelial	  (Caco-­‐2)	  and	  brain	  endothelial	  (RBE4)	  cells:	  Mechanism	  and	  substrate	  specificity.	  European	  Journal	  of	  
Pharmaceutics	  and	  Biopharmaceutics	  70,	  486-­‐492	  (2008).	  
46	  
87	   Lauritzen,	  F.	  et	  al.	  Monocarboxylate	  transporter	  1	  is	  deficient	  on	  microvessels	  in	  the	  human	  epileptogenic	  hippocampus.	  Neurobiol	  Dis	  41,	  577-­‐584,	  doi:10.1016/j.nbd.2010.11.005	  (2011).	  88	   Lauritzen,	  F.	  et	  al.	  Altered	  expression	  of	  brain	  monocarboxylate	  transporter	  1	  in	  models	  of	  temporal	  lobe	  epilepsy.	  Neurobiology	  of	  disease	  45,	  165-­‐176	  (2012).	  89	   Ben-­‐Ari,	  Y.	  Limbic	  seizure	  and	  brain	  damage	  produced	  by	  kainic	  acid:	  mechanisms	  and	  relevance	  to	  human	  temporal	  lobe	  epilepsy.	  Neuroscience	  
14,	  375-­‐403	  (1985).	  90	   Turski,	  W.	  A.	  et	  al.	  Limbic	  seizures	  produced	  by	  pilocarpine	  in	  rats:	  behavioural,	  electroencephalographic	  and	  neuropathological	  study.	  
Behavioural	  brain	  research	  9,	  315-­‐335	  (1983).	  91	   McIntyre,	  D.	  C.,	  Kelly,	  M.	  E.	  &	  Dufresne,	  C.	  FAST	  and	  SLOW	  amygdala	  kindling	  rat	  strains:	  comparison	  of	  amygdala,	  hippocampal,	  piriform	  and	  perirhinal	  cortex	  kindling.	  Epilepsy	  research	  35,	  197-­‐209	  (1999).	  92	   Dube,	  C.	  et	  al.	  Prolonged	  febrile	  seizures	  in	  the	  immature	  rat	  model	  enhance	  hippocampal	  excitability	  long	  term.	  Annals	  of	  Neurology	  47,	  336	  (2000).	  93	   Al-­‐Mudallal,	  A.	  S.,	  LaManna,	  J.	  C.,	  Lust,	  W.	  D.	  &	  Harik,	  S.	  I.	  Diet-­‐induced	  ketosis	  does	  not	  cause	  cerebral	  acidosis.	  Epilepsia	  37,	  258-­‐261	  (1996).	  94	   Bertram,	  E.	  H.,	  Williamson,	  J.	  M.,	  Cornett,	  J.	  F.,	  Spradlin,	  S.	  &	  Chen,	  Z.	  F.	  Design	  and	  construction	  of	  a	  long-­‐term	  continuous	  video-­‐EEG	  monitoring	  unit	  for	  simultaneous	  recording	  of	  multiple	  small	  animals.	  Brain	  Research	  Protocols	  2,	  85-­‐97	  (1997).	  95	   Racine,	  R.	  J.,	  Burnham,	  W.	  M.	  I.,	  Gartner,	  J.	  G.	  &	  Levitan,	  D.	  Rates	  of	  motor	  seizure	  development	  in	  rats	  subjected	  to	  electrical	  brain	  stimulation:	  strain	  and	  inter-­‐stimulation	  interval	  effects.	  Electroencephalography	  and	  clinical	  
neurophysiology	  35,	  553-­‐556	  (1973).	  96	   Wang,	  Y.,	  Zaveri,	  H.	  P.,	  Lee,	  T.	  S.	  W.	  &	  Eid,	  T.	  The	  development	  of	  recurrent	  seizures	  after	  continuous	  intrahippocampal	  infusion	  of	  methionine	  sulfoximine	  in	  rats::	  A	  video-­‐intracranial	  electroencephalographic	  study.	  
Experimental	  neurology	  220,	  293-­‐302	  (2009).	  97	   Rosenfeld,	  W.,	  Sachdeo,	  R.,	  Faught,	  R.	  E.	  &	  Privitera,	  M.	  Long‐Term	  Experience	  with	  Topiramate	  as	  Adjunctive	  Therapy	  and	  as	  Monotherapy	  in	  Patients	  with	  Partial	  Onset	  Seizures:	  Retrospective	  Survey	  of	  Open‐Label	  Treatment.	  Epilepsia	  38,	  S34-­‐S36	  (1997).	  98	   Uhlemann,	  E.	  R.	  &	  Neims,	  A.	  H.	  Anticonvulsant	  properties	  of	  the	  ketogenic	  diet	  in	  mice.	  Journal	  of	  Pharmacology	  and	  Experimental	  Therapeutics	  180,	  231-­‐238	  (1972).	  99	   Stafstrom,	  C.	  E.	  Animal	  models	  of	  the	  ketogenic	  diet:	  what	  have	  we	  learned,	  what	  can	  we	  learn?	  Epilepsy	  research	  37,	  241-­‐259	  (1999).	  100	   Mahoney,	  A.	  W.,	  Hendricks,	  D.	  G.,	  Bernhard,	  N.	  &	  Sisson,	  D.	  V.	  Fasting	  and	  ketogenic	  diet	  effects	  on	  audiogenic	  seizure	  susceptibility	  of	  magnesium	  deficient	  rats.	  Pharmacology	  Biochemistry	  and	  Behavior	  18,	  683-­‐687	  (1983).	  101	   Thavendiranathan,	  P.	  et	  al.	  The	  MCT	  ketogenic	  diet:	  effects	  on	  animal	  seizure	  models.	  Experimental	  neurology	  161,	  696-­‐703	  (2000).	  
47	  
102	   Thavendiranathan,	  P.,	  Chow,	  C.,	  Cunnane,	  S.	  &	  McIntyre	  Burnham,	  W.	  The	  effect	  of	  the	  ‘classic’ketogenic	  diet	  on	  animal	  seizure	  models.	  Brain	  research	  
959,	  206-­‐213	  (2003).	  103	   Bough,	  K.	  J.	  &	  Rho,	  J.	  M.	  Anticonvulsant	  mechanisms	  of	  the	  ketogenic	  diet.	  
Epilepsia	  48,	  43-­‐58	  (2007).	  104	   Keith,	  H.	  M.	  CONVULSIVE	  DISORDERS	  IN	  CHILDREN	  WITH	  REFERENCE	  TO	  TREATMENT	  WITH	  KETOGENIC	  DIET.	  	  (1963).	  105	   Murphy,	  W.	  P.	  	  Vol.	  2010	  	  	  1.	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48	  
Chapter 7: Figure References and Legends 
 
 
 
Figure 1. Timeline of the experiment. Each arrow segment represents 1 week of time. 
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Figure 2. Overview of the temporal distribution of seizures. Thirty-eight animals were 
recorded by continuous video-intracranial  EEG: 26 on standard chow (SC) ad libitum, 
and 12 on a KD with 20% caloric restriction.  Seizure counts are given and the days when 
seizures occurred are highlighted in color. Note the presence of an initial cluster of very 
frequent seizures in most animals. Subsequent clusters of seizures occurred throughout 
the monitoring period. 
 
Animal Group Seizure/Count///24/hrs
VIII SC 21 23 1 1 0 0 0 0 2 2 1 1 2 3 2 2 2 0 4 1 2
IX SC 2 5 1 0 2 3 2 3 7 1 1 0 0 0 0 0 0 0 2 0 1
X SC 32 1 0 0 0 0 0 2 4 0 0 0 2 1 2 3 0 1 2 10 13
XI SC 73 71 34 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
XII SC 0 0 0 4 18 36 62 44 79 40 0 0 0 0 0 0 0 0 0 0 0
XIII SC 18 6 0 0 0 0 1 0 0 0 3 0 0 0 0 3 0 0 1 13 0
XIV SC 38 11 0 0 0 1 1 0 2 1 1 0 0 0 22 1 0 0 1 1 2
XV SC 0 49 5 0 0 0 0 0 0 0 3 4 1 0 0 3 3 1 5 2 1
XVI SC 5 6 0 3 0 2 3 1 2 0 1 1 1 1 2 0 1 0 2 0 1
XVII SC 3 5 0 0 1 1 2 2 1 2 2 0 4 1 1 2 2 1 2 1 1
XVIII SC 3 4 2 1 1 0 3 0 1 0 1 0 3 0 0 0 1 0 2 0 1
XIX SC 4 3 0 0 1 1 1 2 1 1 1 1 0 1 1 2 1 1 1 1 1
XX SC 6 5 2 0 1 2 0 3 1 0 1 0 0 0 0 0 0 0 0 0 0
XXI SC 2 12 1 1 3 2 1 1 0 0 1 0 1 0 0 1 1 1 0 1 0
XXII SC 11 16 0 0 6 4 1 2 2 1 1 1 1 0 1 1 0 1 0 1 1
XXIII SC 2 0 0 0 0 4 5 2 2 3 1 1 1 0 1 2 2 0 2 3 1
XXIV SC 11 2 8 5 4 1 0 0 1 1 1 0 0 2 0 0 1 0 0 0 0
XXV SC 6 5 0 0 0 0 5 0 1 0 1 0 0 0 0 1 0 0 2 0 1
XXXI SC 1 7 0 2 2 1 1 1 0 1 0 2 0 1 1 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0
XXXII SC 0 0 5 5 1 0 0 0 3 4 3 14 15 13 7 13 9 15 3 0 0 0 0 6 2 2 0 0 1 0 0 1 0 0 0
XXXIII SC 0 0 0 0 0 0 0 0 3 0 1 1 1 1 1 2 3 4 0 0 0 0 4 0 6 19 0 0 0 0 0 0 0 0 0
XXXIV SC 6 4 1 0 1 1 3 0 0 2 1 3 0 0 2 0 0 1 0 2 0 0 1 1 1 1 0 0 0 1 1 0 0 0 1
XXXV SC 19 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0
XXXVI SC 21 1 0 0 0 2 0 3 2 0 0 0 0 1 0 1 0 2 1 1 3 0 0 0 2 0 2 0 1 2 0 0 0 0 3
XXXVII SC 0 13 5 0 0 0 1 1 2 0 0 1 1 0 4 3 0 1 0 0 1 1 0 1 0 0 0 1 1 1 0 0 0 0 0
XXXVIII SC 66 3 1 0 0 0 0 1 0 1 1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 3 1 0 0 3 0 0 1 0
I KD 4 7 0 0 0 0 0 0 3 4 3 33 2 0 0 0 0 0 0 0 0
II KD 55 56 50 4 0 0 1 0 1 0 0 2 0 0 0 0 0 1 6 3 0
III KD 17 5 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 2 0 11 6
IV KD 0 2 0 0 0 0 0 2 9 1 0 0 0 0 1 1 1 1 0 0 0
V KD 42 24 0 0 0 0 1 2 2 2 2 1 1 5 5 4 1 1 2 2 0
VI KD 0 0 5 0 4 41 35 42 6 0 0 0 0 1 0 0 0 1 3 0 0
VII KD 0 9 3 0 0 0 0 1 2 1 4 1 0 1 0 0 2 1 8 3 4
XXVI KD 2 3 1 0 0 0 0 0 0 1 3 1 3 0 0 3 1 0 2 0 1 1 0 4 1 0 0 2 2 5 0 0 0 5 0
XXVII KD 13 3 0 0 2 3 2 2 0 0 2 1 2 1 0 0 0 1 0 1 0 0 2 0 0 1 0 0 1 0 0 1 0 1 3
XXVIII KD 0 0 0 12 1 0 3 4 3 2 1 1 1 1 1 1 0 1 0 1 1 1 1 1 0 0 0 0 0 1 1 0 0 0 1
XXIX KD 6 3 4 0 0 1 4 0 1 2 1 0 1 0 1 0 0 0 0 1 1 1 3 1 0 1 1 1 0 0 1 0 0 0 0
XXX KD 2 4 2 0 0 3 3 0 0 0 1 1 1 1 1 2 2 0 1 1 0 0 1 1 1 0 0 0 1 0 1 1 0 1 0
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Fig 3. Plot of the seizure frequency for all animals for the first seven days after MSO 
infusion. The line drawn through the boxes represents the average seizure frequency for 
that particular day.  Note the cluster of initial seizures during days 1-2, followed by a 
decline in seizure frequency during days 3-5, with subsequent smaller increase during 
days 6-7. 
 
 
Fig 4. Average number of seizures each day for both groups of animals. The greatest 
number of seizures for both groups occurred during the first 3 days of the study; there is a 
nadir around day 5, then another peak days 6-9, followed by a slow taper 
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Fig. 5. Weekly frequency of all seizure types (a) and of seizure types at different 
behavioral severities (b-f) in KD treated (blue bars) and standard chow (SC, red bars) 
rats.  All rats were given SC during week 1.  KD started on week 2.    Shown is the mean 
number of seizures. There were no significant differences in seizure frequency or severity 
between KD versus SC treated rats.     
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Figure 6. Blood glucose and ketone levels for a random selection of 8 rats in the KD and 
SC treated groups. Both groups were fed standard chow ad libitum for 7 days to facilitate 
recovery from surgery. The diet group started treatment on day 8. The first measurement 
taken while the rats were on the KD was on day 14. KD rats had significantly decreased 
blood glucose levels on days 14, 21, and 28. KD rats had significantly increased blood 
ketone levels on days 21 and 28. 
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Chapter 8: Tables 
 
Breakfast Lunch Dinner 
2 medium eggs  
1 sausage patty  
11 tsp butter  
3 tbs heavy whipping cream 
2 hot dogs 
2 lettuce leaves, 1 thin slice 
tomato  
3.5 tbs mayonnaise 
Chicken 1.5 ounces  
½ cup green beans, 2 tsp 
butter  
4 tbl vegetable oil 
 
Table 1. Sample ketogenic diet for 1 day (from Sirven et. al) 
 
Diet kcal/g % Protein % Fat % Carbs 
Standard Chow 3.3 20 13 67 
Ketogenic Diet 7.1 8.7 89.2 2.1 
Table 2. Comparison of macronutrients of standard chow vs. KD 
 
 KD: mean # of all 
seizures ± SEM 
SC: mean # of all 
seizures ±SEM 
p-value 
Week 1 36.8 ± 13.8 34.3 ± 7.6 0.86 
Week 2 14.4 ± 4.6 13.8 ± 6.3 0.95 
Week 3 8.0 ± 1.9 9.3 ± 2.1 0.70 
Week 4 5.0 ± 1.2 7.3 ± 3.2 0.61 
Week 5 5.2 ± 1.8 2.1 ± 0.8 0.11 
Table 3. Comparison of the average number of seizures for KD vs. standard chow (SC) 
treated rats. The number of seizures were binned in one week intervals. During week 1, 
all rats are fed SC ad libitum. Treatment with the KD began during week 2.   Student’s t-
test showed no significant reduction of seizures in any week with statistical significance 
determined using the Holm-Sidak method, with alpha = 5%. 
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 KD: mean # of 
seizures ± SEM 
SC: mean # of  
seizures ± SEM 
p-value 
 Stage 1 Stage 1  
Week 1 21.5 ± 5.6 19.0 ± 2.9 0.66 
Week 2 7.2 ± 3.1 5.8 ± 2.4 0.74 
Week 3 2.9 ± 0.9 2.3 ± 0.8 0.67 
Week 4 0.2 ± 0.2 2.8 ± 1.4 0.16 
Week 5 0.2 ± 0.2 0.6 ± 0.3 0.36 
 Stage 2 Stage 2  
Week 1 2.4 ± 1.5 3.6 ± 1.3 0.60 
Week 2 0.8 ± 0.5 2.6 ± 2.0 0.57 
Week 3 0.4 ± 0.2 0.3 ± 0.2 0.59 
Week 4 0.8 ± 0.6 0.1 ± 0.1 0.18 
Week 5 0.2 ± 0.2 0.0 ± 0.0 0.22 
 Stage 3 Stage 3  
Week 1 1.5 ± 0.9 1.3 ± 0.3 0.81 
Week 2 0.8 ± 0.4 0.5 ± 0.2 0.52 
Week 3 0.3 ± 0.2 0.4 ± 0.2 0.62 
Week 4 0.4 ± 0.4 0.0 ± 0.0 0.23 
Week 5 0.0 ± 0.0 0.0 ± 0.0 n/a 
 Stage 4 Stage 4  
Week 1 2.1 ± 1.1 3.2 ± 1.5 0.63 
Week 2 1.1 ± 0.7 1.6 ± 0.7 0.66 
Week 3 1.5 ± 09 2.0 ± 0.7 0.67 
Week 4 2.0 ± 0.7 1.0 ± 0.4 0.21 
Week 5 1.2 ± 0.5 0.1 ± 0.4 0.02 
 Stage 5 Stage 5  
Week 1 8.2 ± 7.1 5.5 ± 2.6 0.65 
Week 2 3.7 ± 3.1 3.1 ± 1.3 0.84 
Week 3 2.3 ± 1.3 3.8 ± 0.9 0.32 
Week 4 1.4 ± 0.6 3.3 ± 2.0 0.50 
Week 5 2.6 ± 1.3  1.1 ± 0.4 0.22 
Table 4. Mean number of seizure for KD and SC rats sorted by severity.  
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 KD: Mean Blood 
Glucose Levels 
mg/dL ± SEM 
SC: Mean  Blood 
Glucose Levels 
mg/dL ± SEM 
p-value 
Day 0 133 ± 5.9 151 ± 7.5 0.08 
Day 7 138 ± 5.6 140 ± 5.0 0.91 
Day 14 116 ± 5.8 137 ± 3.4 0.005* 
Day 21 111 ± 2.7 139 ± 7.0 0.004* 
Day 28 114 ± 3.2 132 ± 5.8 0.019* 
Day 35 113 ± 6.7 No Data N/A 
Table 5. Mean blood glucose levels for KD and SC rats. Significant differences are 
marked with and asterisk 
 
 KD: Mean Blood 
Ketone Levels 
mm/dL ± SEM 
SC: Mean Blood 
Ketone Levels 
mm/dL ± SEM 
p-value 
Day 0 0.39 ± 0.05 0.38 ± 0.06 0.87 
Day 7 0.38 ± 0.06 0.26 ± 0.03 0.10 
Day 14 No Data 0.33 ± 0.03 N/A 
Day 21 1.04 ± 0.10 0.36 ± 0.03 < 0.0001* 
Day 28 0.97 ± 0.04 0.39 ± 0.05  <0.0001* 
Day 35 1.17 ± 0.07 No Data N/A 
Table 6. Mean blood ketone levels for KD and SC rats. Significant differences are 
marked with an asterisk 
 
 
 
 
 
 
 
